thalidomide and Peripheral Nerve Diseases studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research Excerpts

Excerpt	Relevance	Reference
"Bortezomib is active in heavily pretreated multiple myeloma patients; the dose-limiting toxicity is peripheral neuropathy (PN)."	10.22	Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. ( Akpek, G; Badros, A; Can, I; Dalal, JS; Fenton, RG; Goloubeva, O; Heyman, M; Rapoport, AP; Thompson, J, 2007)
"The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy."	9.24	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. ( Avivi, I; Berg, D; Einsele, H; Esseltine, DL; Gupta, N; Hájek, R; Hari, P; Kumar, S; Liberati, AM; Lin, J; Lonial, S; Ludwig, H; Masszi, T; Mateos, MV; Minnema, MC; Moreau, P; Richardson, PG; Romeril, K; Shustik, C; Spencer, A, 2017)
"The phase III trial GEM05MENOS65 randomized 390 patients 65 years old or younger with newly diagnosed symptomatic multiple myeloma (MM) to receive induction with thalidomide/dexamethasone, bortezomib/thalidomide/dexamethasone and Vincristine, BCNU, melphalan, cyclophosphamide, prednisone/vincristine, BCNU, doxorubicin, dexamethasone bortezomib (VBMCP/VBAD/B) followed by autologous stem cell transplantation (ASCT) with MEL-200."	9.24	Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial. ( Alegre, A; Bladé, J; Blanchard, M; Cibeira, M; de Arriba, F; de la Guía, AL; de la Rubia, J; Etxebeste, M; González, Y; Granell, M; Hernández, MT; Lahuerta, JJ; Martínez-López, J; Martínez-Martínez, R; Mateos, M; Oriol, A; Palomera, L; Rosiñol, L; Sampol, M; San Miguel, J; Teruel, AI, 2017)
"Panobinostat 20 mg in combination with bortezomib, thalidomide, and dexamethasone is an efficacious and well tolerated regimen for patients with relapsed multiple myeloma."	9.22	Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. ( Brown, SR; Cavenagh, J; Cook, G; Flanagan, L; Gregory, W; Hall, A; Kishore, B; Low, E; Oakervee, H; Popat, R; Streetly, M; Yong, K, 2016)
"A previous interim report of MM-011, the first study that combined lenalidomide with anthracycline-based chemotherapy followed by lenalidomide maintenance for relapsed and/or refractory multiple myeloma (RRMM), showed promising safety and activity."	9.19	Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma. ( Andresen, S; Ann Karam, M; Baz, R; Bruening, K; Dean, R; Faiman, B; Habecker, B; Hamilton, K; Hussein, MA; Kalaycio, M; Knight, R; Lazaryan, A; Reed, J; Reu, FJ; Sobecks, R; Srkalovic, G; Sweetenham, JW; Waksman, J; Zeldis, JB, 2014)
"Bortezomib and thalidomide significantly improved OS in multiple myeloma patients not eligible for transplantation."	9.19	Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. ( Benevolo, G; Boccadoro, M; Bringhen, S; Cavo, M; Di Raimondo, F; Falcone, AP; Franceschini, L; Gaidano, G; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Magarotto, V; Marasca, R; Mina, R; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, ID; Zambello, R, 2014)
"This single-arm study evaluated feasibility, safety, and initial efficacy of electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy (PN) in cancer patients with multiple myeloma."	9.19	Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. ( Alexanian, R; Badillo, M; Chen, Y; Chiang, J; Cohen, L; Delasalle, K; Garcia, MK; Green, V; Guo, Y; Lee, R; Orlowski, RZ; Romaguera, J; Shah, J; Thomas, S; Wang, M; Weber, D; Wei, Q; You, B; Zhang, L; Zhou, Y, 2014)
"A subanalysis of the GIMEMA-MMY-3006 trial was performed to characterize treatment-emergent peripheral neuropathy (PN) in patients randomized to thalidomide-dexamethasone (TD) or bortezomib-TD (VTD) before and after double autologous transplantation (ASCT) for multiple myeloma (MM)."	9.19	Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. ( Baldini, L; Cavaletti, G; Cavo, M; Elice, F; Galli, M; Gozzetti, A; Lazzaro, A; Martello, M; Montefusco, V; Palumbo, A; Pantani, L; Peccatori, J; Petrucci, MT; Pezzi, A; Rocchi, S; Ruggieri, M; Tacchetti, P; Terragna, C; Tosi, P; Zamagni, E, 2014)
"We aimed to determine the incidence of sensory symptoms (SS) that complicate thalidomide treatment of patients with age-related macular degeneration."	9.14	A prospective double-blind, placebo-controlled study of thalidomide sensory symptoms in an elderly population with age-related macular degeneration. ( Khella, SL; Souayah, N, 2010)
"Fifty patients with multiple myeloma >or=75 years of age received primary treatment with melphalan (M) 8 mg/m(2) on days 1-4, dexamethasone (D) 12 mg/m2 on days 1-4 and 17-20 and thalidomide (T) 300 mg at bedtime on days 1-4 and 17-20."	9.12	Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. ( Anagnostopoulos, A; Anagnostopoulos, N; Delibasi, S; Dimopoulos, MA; Katodritou, E; Kyrtsonis, MC; Maniatis, A; Pouli, A; Repoussis, P; Terpos, E; Vassou, A; Zervas, K; Zomas, A, 2006)
"This phase II study evaluated the combination of semaxanib, a small molecule tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptor-2, and thalidomide in patients with metastatic melanoma to assess the efficacy, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the combination."	9.12	A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. ( Beeram, M; Berg, K; de Bono, JS; Eckhart, SG; Forero, L; Hammond, LA; Izbicka, E; Mita, AC; Mita, MM; Patnaik, A; Rowinsky, EK; Simmons, P; Takimoto, C; Tolcher, AW; Weiss, GR, 2007)
"We report the results of a non-randomized phase II study of low-dose thalidomide plus low-dose dexamethasone therapy in 66 patients with refractory multiple myeloma."	9.12	Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. ( Abe, M; Fujii, H; Fukuhara, T; Handa, H; Hata, H; Iida, S; Ishida, T; Ishii, A; Ishikawa, T; Kosaka, M; Miyata, A; Murakami, H; Oota, M; Ozaki, S; Sakai, A; Sawamura, M; Shimazaki, C; Shimizu, K; Takagi, T; Takatsuki, K; Wakayama, T, 2007)
"Thalidomide is effective as a first-line therapy for the treatment of multiple myeloma (MM), but its use is limited by peripheral neurotoxicity."	9.12	Neuropathy in multiple myeloma treated with thalidomide: a prospective study. ( Bartolomei, I; Cangini, D; Cavo, M; Michelucci, R; Pastorelli, F; Petracci, E; Plasmati, R; Salvi, F; Tacchetti, P; Tassinari, CA; Tosi, P; Zamagni, E, 2007)
"Thalidomide has demonstrated a remarkable efficacy in the treatment of multiple myeloma but its use may cause several toxicities."	9.11	Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. ( Brunori, M; Candela, M; Capelli, D; Catarini, M; Corvatta, L; Leoni, P; Malerba, L; Marconi, M; Mele, A; Montanari, M; Offidani, M; Olivieri, A; Rupoli, S, 2004)
"To evaluate safety and efficacy of thalidomide in the treatment of prurigo nodularis in a group of human immunodeficiency virus (HIV)-infected patients whose condition was recalcitrant to standard treatment."	9.11	Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. ( Berger, T; Maurer, T; Poncelet, A, 2004)
"Thalidomide is remarkably active in advanced relapsed and refractory multiple myeloma (MM), so that its use has been recently proposed either in newly diagnosed patients or as maintenance treatment after conventional or high-dose therapy."	9.11	Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. ( Baccarani, M; Cangini, D; Cavo, M; Cellini, C; Pastorelli, F; Perrone, G; Plasmati, R; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E, 2005)
"An open-label phase I trial of thalidomide (TL) in 20 patients with neurofibromatosis 1 (NF1) treated symptomatic plexiform neurofibroma (PNF)."	9.10	Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1. ( Cohen, BH; Gupta, A; Packer, RJ; Phillips, PC; Ruggieri, P, 2003)
" Thalidomide was well tolerated, with constipation and sedation being the major toxicities."	9.09	Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. ( Black, PM; Figg, WD; Fine, HA; Jaeckle, K; Kaplan, R; Kyritsis, AP; Levin, VA; Loeffler, JS; Pluda, JM; Wen, PY; Yung, WK, 2000)
"This overview summarizes evidence for the efficacy and safety of bortezomib, thalidomide, and lenalidomide in patients with multiple myeloma."	8.95	Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses. ( Aguiar, PM; Colleoni, GWB; de Mendonça Lima, T; Storpirtis, S, 2017)
"In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM)."	8.90	Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. ( Cavo, M; Davies, FE; Delforge, M; Dimopoulos, MA; Facon, T; Hansson, M; Leleu, X; Ludwig, H; Mateos, MV; Miguel, JF; Moreau, P; Morgan, GJ; Palumbo, A; Schey, SA; Sonneveld, P; Weisel, K; Zweegman, S, 2014)
"Thalidomide monotherapy in relapsed/refractory multiple myeloma (MM) has a response rate of 30%."	8.84	A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. ( Bargou, R; Cook, G; Furkert, K; Glasmacher, A; Hahn-Ast, C; Hoffmann, F; Naumann, R; von Lilienfeld-Toal, M, 2008)
"The activity of thalidomide in relapsed or refractory multiple myeloma is widely accepted but not yet demonstrated in a randomised-controlled trial."	8.83	A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. ( Glasmacher, A; Goldschmidt, H; Gorschlüter, M; Hahn, C; Hoffmann, F; Naumann, R; Orlopp, K; Schmidt-Wolf, I; von Lilienfeld-Toal, M, 2006)
"Thalidomide is commonly used in treatment of multiple myeloma (MM)."	7.91	Polymorphisms in the promotor region of the CRBN gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients. ( Chocholska, S; Homa-Mlak, I; Hus, M; Jankowska-Łęcka, O; Mazurek, M; Małecka-Massalska, T; Mielnik, M; Mlak, R; Szczyrek, M; Szudy-Szczyrek, A, 2019)
"Bortezomib- and thalidomide-based therapies have significantly contributed to improved survival of multiple myeloma (MM) patients."	7.85	Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array. ( Alcoceba, M; Barrio, S; Blanchard, MJ; Chillon, MC; Corchete, LA; de la Rubia, J; García-Álvarez, M; García-Sanz, R; González Díaz, M; Jiménez, C; Lahuerta, JJ; Martínez, R; Martínez-López, J; Mateos, MV; Oriol, A; Prieto, I; Puig, N; Rapado, I; San Miguel, JF; Sarasquete, ME, 2017)
" We studied the relationship between 25-hydroxyvitamin D (25D) levels and motor and sensory peripheral neuropathy (PN) among multiple myeloma (MM) patients who have been treated with bortezomib and/or thalidomide."	7.83	Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy. ( Berenson, JR; Bravin, E; Ibrahim, E; Masri, M; Spektor, TM; Swift, RA; Treisman, J; Udd, KA; Vidisheva, A; Wang, J, 2016)
"In order to evaluate the main adverse effects of drug protocols using bortezomib and/or thalidomide for the treatment of multiple myeloma, we conducted a prospective study."	7.83	Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide. ( Atalla, A; Castro, TB; Hallack Neto, AE; Ribeiro, LC, 2016)
"Thalidomide, a sedative popular in the 1950s and withdrawn from the market in the 1960s because of its teratogenic effects, has emerged again on the market in the last decade as an effective agent in the treatment of multiple myeloma."	7.81	[Thalidomide induced peripheral neuropathy in multiple myeloma patients]. ( Banach, M; Jurczyszyn, A; Skotnicki, A, 2015)
"Lenalidomide and dexamethasone (RD) is a standard of care for relapsed/refractory multiple myeloma (RRMM), but there is limited published data on its efficacy and safety in the "real world" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition."	7.80	"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. ( Anagnostopoulos, N; Anargyrou, K; Briasoulis, E; Giannakoulas, N; Hatzimichael, E; Karras, G; Katodritou, E; Kotsopoulou, M; Kyriakou, D; Kyrtsonis, MC; Lalagianni, C; Maniatis, A; Matsouka, P; Michali, E; Papageorgiou, G; Spanoudakis, E; Symeonidis, A; Terpos, E; Tsakiridou, A; Tsionos, K; Vadikolia, C; Zikos, P, 2014)
"The aim of the study was to evaluate thalidomide as rescue therapy for pediatric patients with severe refractory Crohn disease (CD) who failed to respond to antitumor necrosis factor (TNF) biologic agents."	7.78	Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab. ( Felipez, LM; Gokhale, R; Kirschner, BS; Tierney, MP, 2012)
"The aim of this study was to describe the use of thalidomide in the treatment of prurigo nodularis Hyde (PNH) refractory to other treatments or in cases where other treatments cannot be used due to side effects."	7.77	Thalidomide in 42 patients with prurigo nodularis Hyde. ( Andersen, TP; Fogh, K, 2011)
"Bortezomib is a first-in-class proteasome inhibitor with remarkable antitumor activity that is approved for the treatment of patients with multiple myeloma."	7.74	Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma. ( Auran-Schleinitz, T; Blaise, D; Bouabdallah, R; Coso, D; de Collela, JM; de Lavallade, H; El-Cheikh, J; Gastaut, JA; Mohty, M; Stoppa, AM, 2008)
"To investigate the effects of thalidomide treatment for POEMS syndrome."	7.74	Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome. ( Hattori, T; Kanai, K; Kuwabara, S; Misawa, S; Nakaseko, C; Nishimura, M; Sawai, S, 2008)
"Three cases of multiple myeloma treated with thalidomide are presented which highlight therapeutic dilemmas presented by therapy with this new agent."	7.71	Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions. ( Desikan, RK; Jagannath, S, 2001)
"We examined the efficacy of thalidomide in 34 patients with myelodysplastic syndromes (MDS): five RAEB-T, four RAEB, three CMML, six RARS, and 16 RA."	7.71	Thalidomide for the treatment of patients with myelodysplastic syndromes. ( Aivado, M; Gattermann, N; Germing, U; Haas, R; Misgeld, E; Strupp, C, 2002)
" In routine practice, few patients received ixazomib-based induction therapy due to reasons including (1) patients' preference on oral regimens, (2) concerns on adverse events (AEs) of other intravenous/subcutaneous regimens, (3) requirements for less center visits, and (4) fears of COVID-19 and other infectious disease exposures."	6.94	Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study. ( Bao, L; Chen, B; Ding, K; Fu, C; Hua, L; Huang, Y; Li, B; Li, J; Liu, P; Luo, J; Wang, L; Wang, S; Wang, W; Wu, G; Xia, Z; Xu, T; Yang, W; Yang, Y; Zhang, W; Zhou, X, 2020)
"Thrombocytopenia was the most common grade ≥ 3 AE (35%)."	6.78	A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. ( Allietta, N; Angermund, R; Bladé, J; Blau, IW; Broer, E; Corradini, P; Dimopoulos, MA; Drach, J; Giraldo, P; Mitchell, V; Petrucci, MT; Teixeira, A, 2013)
" Nonhematologic grade 3/4 adverse events were reported in 35% of once-weekly patients and 51% of twice-weekly patients (P = ."	6.75	Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. ( Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Cavalli, M; Cavo, M; De Rosa, L; Evangelista, A; Falcone, AP; Gaidano, G; Gentili, S; Genuardi, M; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Liberati, AM; Musto, P; Nozzoli, C; Palumbo, A; Patriarca, F; Ria, R; Rizzo, V; Rossi, D, 2010)
"Significant peripheral neuropathy and deep vein thrombosis each occurred in only 3%."	6.72	A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ( Alsina, M; Anderson, KC; Blood, E; Dalton, WS; Desikan, KR; Doss, D; Freeman, A; Gorelik, S; Hideshima, T; Jagannath, S; Kelly-Colson, K; Knight, R; McKenney, ML; Mitsiades, CS; Munshi, NC; Olesnyckyj, M; Rajkumar, SV; Rich, R; Richardson, PG; Schlossman, RL; Warren, D; Weller, E; Wride, K; Wu, A; Zeldenrust, SR; Zeldis, J, 2006)
"Thalidomide was developed in the 1950s as a sedative having only a low toxicity."	6.42	[New pharmacological availability of thalidomide based on experience in patients with multiple myeloma]. ( Murakami, H, 2004)
"Bortezomib is active in heavily pretreated multiple myeloma patients; the dose-limiting toxicity is peripheral neuropathy (PN)."	6.22	Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. ( Akpek, G; Badros, A; Can, I; Dalal, JS; Fenton, RG; Goloubeva, O; Heyman, M; Rapoport, AP; Thompson, J, 2007)
"The incidence of multiple myeloma (MM) is two to three times higher in Black patients compared with other races, making it the most common hematologic malignancy in this patient population."	5.91	Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction. ( Cao, Y; Dhodapkar, M; Hall, KH; Harvey, RD; Hofmeister, CC; Joseph, NS; Kaufman, JL; Liu, Y; Lonial, S; Maples, KT; Nooka, AK; Sun, LF, 2023)
"We analyzed DNA from 1,495 patients with multiple myeloma."	5.37	Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. ( Child, JA; Corthals, SL; Davies, FE; Dickens, NJ; Durie, BG; Goldschmidt, H; Gregory, WM; Johnson, DC; Lokhorst, HM; Morgan, GJ; Ross, FM; Sonneveld, P; Van Ness, B; Walker, BA, 2011)
"Bortezomib has been shown to be highly active in MM patients with RI."	5.36	Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. ( Baldini, L; Boccadoro, M; Bringhen, S; Callea, V; Casulli, AF; Catalano, L; Cavo, M; Ciolli, S; Di Raimondo, F; Galimberti, S; Gentile, M; Mannina, D; Mele, G; Morabito, F; Musto, P; Offidani, M; Palmieri, S; Palumbo, A; Petrucci, MT; Pinotti, G; Piro, E; Tosi, P, 2010)
"Thalidomide is an anti-neoplastic agent with anti-angiogenic and other mechanisms of action."	5.34	Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma. ( Chan, P; Cheung, TT; Chok, SH; Epstein, RJ; Fan, ST; Lam, V; Ng, KK; Poon, RT; Wong, H; Yau, T, 2007)
"The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy."	5.24	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. ( Avivi, I; Berg, D; Einsele, H; Esseltine, DL; Gupta, N; Hájek, R; Hari, P; Kumar, S; Liberati, AM; Lin, J; Lonial, S; Ludwig, H; Masszi, T; Mateos, MV; Minnema, MC; Moreau, P; Richardson, PG; Romeril, K; Shustik, C; Spencer, A, 2017)
"The phase III trial GEM05MENOS65 randomized 390 patients 65 years old or younger with newly diagnosed symptomatic multiple myeloma (MM) to receive induction with thalidomide/dexamethasone, bortezomib/thalidomide/dexamethasone and Vincristine, BCNU, melphalan, cyclophosphamide, prednisone/vincristine, BCNU, doxorubicin, dexamethasone bortezomib (VBMCP/VBAD/B) followed by autologous stem cell transplantation (ASCT) with MEL-200."	5.24	Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial. ( Alegre, A; Bladé, J; Blanchard, M; Cibeira, M; de Arriba, F; de la Guía, AL; de la Rubia, J; Etxebeste, M; González, Y; Granell, M; Hernández, MT; Lahuerta, JJ; Martínez-López, J; Martínez-Martínez, R; Mateos, M; Oriol, A; Palomera, L; Rosiñol, L; Sampol, M; San Miguel, J; Teruel, AI, 2017)
"Panobinostat 20 mg in combination with bortezomib, thalidomide, and dexamethasone is an efficacious and well tolerated regimen for patients with relapsed multiple myeloma."	5.22	Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. ( Brown, SR; Cavenagh, J; Cook, G; Flanagan, L; Gregory, W; Hall, A; Kishore, B; Low, E; Oakervee, H; Popat, R; Streetly, M; Yong, K, 2016)
"A previous interim report of MM-011, the first study that combined lenalidomide with anthracycline-based chemotherapy followed by lenalidomide maintenance for relapsed and/or refractory multiple myeloma (RRMM), showed promising safety and activity."	5.19	Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma. ( Andresen, S; Ann Karam, M; Baz, R; Bruening, K; Dean, R; Faiman, B; Habecker, B; Hamilton, K; Hussein, MA; Kalaycio, M; Knight, R; Lazaryan, A; Reed, J; Reu, FJ; Sobecks, R; Srkalovic, G; Sweetenham, JW; Waksman, J; Zeldis, JB, 2014)
"Bortezomib and thalidomide significantly improved OS in multiple myeloma patients not eligible for transplantation."	5.19	Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. ( Benevolo, G; Boccadoro, M; Bringhen, S; Cavo, M; Di Raimondo, F; Falcone, AP; Franceschini, L; Gaidano, G; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Magarotto, V; Marasca, R; Mina, R; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, ID; Zambello, R, 2014)
"This single-arm study evaluated feasibility, safety, and initial efficacy of electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy (PN) in cancer patients with multiple myeloma."	5.19	Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. ( Alexanian, R; Badillo, M; Chen, Y; Chiang, J; Cohen, L; Delasalle, K; Garcia, MK; Green, V; Guo, Y; Lee, R; Orlowski, RZ; Romaguera, J; Shah, J; Thomas, S; Wang, M; Weber, D; Wei, Q; You, B; Zhang, L; Zhou, Y, 2014)
"A subanalysis of the GIMEMA-MMY-3006 trial was performed to characterize treatment-emergent peripheral neuropathy (PN) in patients randomized to thalidomide-dexamethasone (TD) or bortezomib-TD (VTD) before and after double autologous transplantation (ASCT) for multiple myeloma (MM)."	5.19	Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. ( Baldini, L; Cavaletti, G; Cavo, M; Elice, F; Galli, M; Gozzetti, A; Lazzaro, A; Martello, M; Montefusco, V; Palumbo, A; Pantani, L; Peccatori, J; Petrucci, MT; Pezzi, A; Rocchi, S; Ruggieri, M; Tacchetti, P; Terragna, C; Tosi, P; Zamagni, E, 2014)
"We aimed to determine the incidence of sensory symptoms (SS) that complicate thalidomide treatment of patients with age-related macular degeneration."	5.14	A prospective double-blind, placebo-controlled study of thalidomide sensory symptoms in an elderly population with age-related macular degeneration. ( Khella, SL; Souayah, N, 2010)
"We report the long-term follow-up results of a phase II trial of thalidomide for early-stage multiple myeloma (MM)."	5.14	Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. ( Detweiler-Short, K; Dispenzieri, A; Gertz, MA; Greipp, PR; Hayman, S; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Russell, SJ; Vincent Rajkumar, S; Witzig, TE; Zeldenrust, SR, 2010)
"Fifty patients with multiple myeloma >or=75 years of age received primary treatment with melphalan (M) 8 mg/m(2) on days 1-4, dexamethasone (D) 12 mg/m2 on days 1-4 and 17-20 and thalidomide (T) 300 mg at bedtime on days 1-4 and 17-20."	5.12	Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. ( Anagnostopoulos, A; Anagnostopoulos, N; Delibasi, S; Dimopoulos, MA; Katodritou, E; Kyrtsonis, MC; Maniatis, A; Pouli, A; Repoussis, P; Terpos, E; Vassou, A; Zervas, K; Zomas, A, 2006)
"This phase II study evaluated the combination of semaxanib, a small molecule tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptor-2, and thalidomide in patients with metastatic melanoma to assess the efficacy, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the combination."	5.12	A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. ( Beeram, M; Berg, K; de Bono, JS; Eckhart, SG; Forero, L; Hammond, LA; Izbicka, E; Mita, AC; Mita, MM; Patnaik, A; Rowinsky, EK; Simmons, P; Takimoto, C; Tolcher, AW; Weiss, GR, 2007)
"Peripheral neuropathy frequently limits the duration of treatment with thalidomide for patients with multiple myeloma."	5.12	Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. ( Day, B; Mileshkin, L; Prince, HM; Seymour, JF; Stark, R; Zeldis, JB, 2006)
"We report the results of a non-randomized phase II study of low-dose thalidomide plus low-dose dexamethasone therapy in 66 patients with refractory multiple myeloma."	5.12	Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. ( Abe, M; Fujii, H; Fukuhara, T; Handa, H; Hata, H; Iida, S; Ishida, T; Ishii, A; Ishikawa, T; Kosaka, M; Miyata, A; Murakami, H; Oota, M; Ozaki, S; Sakai, A; Sawamura, M; Shimazaki, C; Shimizu, K; Takagi, T; Takatsuki, K; Wakayama, T, 2007)
"Thalidomide is effective as a first-line therapy for the treatment of multiple myeloma (MM), but its use is limited by peripheral neurotoxicity."	5.12	Neuropathy in multiple myeloma treated with thalidomide: a prospective study. ( Bartolomei, I; Cangini, D; Cavo, M; Michelucci, R; Pastorelli, F; Petracci, E; Plasmati, R; Salvi, F; Tacchetti, P; Tassinari, CA; Tosi, P; Zamagni, E, 2007)
"Thalidomide has demonstrated a remarkable efficacy in the treatment of multiple myeloma but its use may cause several toxicities."	5.11	Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. ( Brunori, M; Candela, M; Capelli, D; Catarini, M; Corvatta, L; Leoni, P; Malerba, L; Marconi, M; Mele, A; Montanari, M; Offidani, M; Olivieri, A; Rupoli, S, 2004)
"To evaluate safety and efficacy of thalidomide in the treatment of prurigo nodularis in a group of human immunodeficiency virus (HIV)-infected patients whose condition was recalcitrant to standard treatment."	5.11	Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. ( Berger, T; Maurer, T; Poncelet, A, 2004)
"Thalidomide is remarkably active in advanced relapsed and refractory multiple myeloma (MM), so that its use has been recently proposed either in newly diagnosed patients or as maintenance treatment after conventional or high-dose therapy."	5.11	Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. ( Baccarani, M; Cangini, D; Cavo, M; Cellini, C; Pastorelli, F; Perrone, G; Plasmati, R; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E, 2005)
"An open-label phase I trial of thalidomide (TL) in 20 patients with neurofibromatosis 1 (NF1) treated symptomatic plexiform neurofibroma (PNF)."	5.10	Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1. ( Cohen, BH; Gupta, A; Packer, RJ; Phillips, PC; Ruggieri, P, 2003)
" Thalidomide was well tolerated, with constipation and sedation being the major toxicities."	5.09	Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. ( Black, PM; Figg, WD; Fine, HA; Jaeckle, K; Kaplan, R; Kyritsis, AP; Levin, VA; Loeffler, JS; Pluda, JM; Wen, PY; Yung, WK, 2000)
"This overview summarizes evidence for the efficacy and safety of bortezomib, thalidomide, and lenalidomide in patients with multiple myeloma."	4.95	Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses. ( Aguiar, PM; Colleoni, GWB; de Mendonça Lima, T; Storpirtis, S, 2017)
" Lenalidomide, a more potent second generation IMiD with fewer side effects than thalidomide, is commonly used in newly-diagnosed multiple myeloma, relapsed refractory myeloma and as maintenance therapy after autologous stem cell transplantation (ASCT)."	4.95	Immunomodulatory Drugs (IMiDs) in Multiple Myeloma. ( Lentzsch, S; Raza, S; Safyan, RA, 2017)
"Thalidomide- or lenalidomide-based maintenance therapy improves PFS but not OS in MM and increases risks of grade 3-4 adverse events, including thromboembolism, peripheral neuropathy, neutropenia, and infection."	4.93	Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. ( Andersson, BS; Berenson, JR; Champlin, RE; Chang, VT; Guan, X; Qazilbash, MH; Shen, Y; Wang, J; Wang, ML; Wang, Y; Yang, F; Zhang, W, 2016)
"In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM)."	4.90	Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. ( Cavo, M; Davies, FE; Delforge, M; Dimopoulos, MA; Facon, T; Hansson, M; Leleu, X; Ludwig, H; Mateos, MV; Miguel, JF; Moreau, P; Morgan, GJ; Palumbo, A; Schey, SA; Sonneveld, P; Weisel, K; Zweegman, S, 2014)
"After decades of disuse because of its teratogenic effects, thalidomide has had a resurgence of use as a promising therapeutic agent for multiple myeloma."	4.86	Palliative oncology: thalidomide. ( Prommer, EE, 2010)
"The introduction of novel antimyeloma therapies, including thalidomide, lenalidomide and bortezomib, has expanded treatment options for patients with multiple myeloma."	4.86	Management of treatment-related adverse events in patients with multiple myeloma. ( Mateos, MV, 2010)
"Introduction of the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and lenalidomide has substantially improved outcomes for patients with multiple myeloma."	4.86	Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. ( Bladé, J; Delforge, M; Dimopoulos, MA; Facon, T; Kropff, M; Ludwig, H; Palumbo, A; San-Miguel, JF; Sonneveld, P; Van Damme, P, 2010)
"Thalidomide and bortezomib are remarkably efficacious in the treatment of multiple myeloma."	4.85	Multiple myeloma, painful neuropathy, acupuncture? ( Chang, DZ; Chiang, J; Delasalle, K; Fang, W; Forman, A; Garcia, MK; Guo, Y; Lu, J; Romaguera, J; Wang, M; Yi, Q; Zhou, Y, 2009)
"Thalidomide monotherapy in relapsed/refractory multiple myeloma (MM) has a response rate of 30%."	4.84	A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. ( Bargou, R; Cook, G; Furkert, K; Glasmacher, A; Hahn-Ast, C; Hoffmann, F; Naumann, R; von Lilienfeld-Toal, M, 2008)
"The activity of thalidomide in relapsed or refractory multiple myeloma is widely accepted but not yet demonstrated in a randomised-controlled trial."	4.83	A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. ( Glasmacher, A; Goldschmidt, H; Gorschlüter, M; Hahn, C; Hoffmann, F; Naumann, R; Orlopp, K; Schmidt-Wolf, I; von Lilienfeld-Toal, M, 2006)
"Thalidomide is commonly used in treatment of multiple myeloma (MM)."	3.91	Polymorphisms in the promotor region of the CRBN gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients. ( Chocholska, S; Homa-Mlak, I; Hus, M; Jankowska-Łęcka, O; Mazurek, M; Małecka-Massalska, T; Mielnik, M; Mlak, R; Szczyrek, M; Szudy-Szczyrek, A, 2019)
"Bortezomib- and thalidomide-based therapies have significantly contributed to improved survival of multiple myeloma (MM) patients."	3.85	Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array. ( Alcoceba, M; Barrio, S; Blanchard, MJ; Chillon, MC; Corchete, LA; de la Rubia, J; García-Álvarez, M; García-Sanz, R; González Díaz, M; Jiménez, C; Lahuerta, JJ; Martínez, R; Martínez-López, J; Mateos, MV; Oriol, A; Prieto, I; Puig, N; Rapado, I; San Miguel, JF; Sarasquete, ME, 2017)
" We studied the relationship between 25-hydroxyvitamin D (25D) levels and motor and sensory peripheral neuropathy (PN) among multiple myeloma (MM) patients who have been treated with bortezomib and/or thalidomide."	3.83	Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy. ( Berenson, JR; Bravin, E; Ibrahim, E; Masri, M; Spektor, TM; Swift, RA; Treisman, J; Udd, KA; Vidisheva, A; Wang, J, 2016)
"In order to evaluate the main adverse effects of drug protocols using bortezomib and/or thalidomide for the treatment of multiple myeloma, we conducted a prospective study."	3.83	Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide. ( Atalla, A; Castro, TB; Hallack Neto, AE; Ribeiro, LC, 2016)
"2 years) underwent clinical and neurophysiologic assessment at baseline and at 2 (8 patients, group A) or 5 years (11 patients, group B) after starting lenalidomide therapy for relapsed/refractory multiple myeloma."	3.83	Lenalidomide long-term neurotoxicity: Clinical and neurophysiologic prospective study. ( Barilà, G; Berno, T; Briani, C; Cacciavillani, M; Campagnolo, M; Dalla Torre, C; De March, E; Ermani, M; Lico, A; Lucchetta, M; Salvalaggio, A; Zambello, R, 2016)
"Thalidomide, a sedative popular in the 1950s and withdrawn from the market in the 1960s because of its teratogenic effects, has emerged again on the market in the last decade as an effective agent in the treatment of multiple myeloma."	3.81	[Thalidomide induced peripheral neuropathy in multiple myeloma patients]. ( Banach, M; Jurczyszyn, A; Skotnicki, A, 2015)
"Lenalidomide and dexamethasone (RD) is a standard of care for relapsed/refractory multiple myeloma (RRMM), but there is limited published data on its efficacy and safety in the "real world" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition."	3.80	"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. ( Anagnostopoulos, N; Anargyrou, K; Briasoulis, E; Giannakoulas, N; Hatzimichael, E; Karras, G; Katodritou, E; Kotsopoulou, M; Kyriakou, D; Kyrtsonis, MC; Lalagianni, C; Maniatis, A; Matsouka, P; Michali, E; Papageorgiou, G; Spanoudakis, E; Symeonidis, A; Terpos, E; Tsakiridou, A; Tsionos, K; Vadikolia, C; Zikos, P, 2014)
"The aim of the study was to evaluate thalidomide as rescue therapy for pediatric patients with severe refractory Crohn disease (CD) who failed to respond to antitumor necrosis factor (TNF) biologic agents."	3.78	Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab. ( Felipez, LM; Gokhale, R; Kirschner, BS; Tierney, MP, 2012)
"The aim of this study was to describe the use of thalidomide in the treatment of prurigo nodularis Hyde (PNH) refractory to other treatments or in cases where other treatments cannot be used due to side effects."	3.77	Thalidomide in 42 patients with prurigo nodularis Hyde. ( Andersen, TP; Fogh, K, 2011)
"Fifteen patients who had previously received 100 mg/day of thalidomide for the treatment of multiple myeloma were evaluated retrospectively."	3.75	Clinical and electrophysiological evaluation of patients with thalidomide-induced neuropathy. ( Aki, Z; Erdogmus, NI; Haznedar, R; Kocer, B; Kuruoglu, R; Sucak, G, 2009)
"Bortezomib is a first-in-class proteasome inhibitor with remarkable antitumor activity that is approved for the treatment of patients with multiple myeloma."	3.74	Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma. ( Auran-Schleinitz, T; Blaise, D; Bouabdallah, R; Coso, D; de Collela, JM; de Lavallade, H; El-Cheikh, J; Gastaut, JA; Mohty, M; Stoppa, AM, 2008)
"To investigate the effects of thalidomide treatment for POEMS syndrome."	3.74	Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome. ( Hattori, T; Kanai, K; Kuwabara, S; Misawa, S; Nakaseko, C; Nishimura, M; Sawai, S, 2008)
"Three cases of multiple myeloma treated with thalidomide are presented which highlight therapeutic dilemmas presented by therapy with this new agent."	3.71	Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions. ( Desikan, RK; Jagannath, S, 2001)
"We examined the efficacy of thalidomide in 34 patients with myelodysplastic syndromes (MDS): five RAEB-T, four RAEB, three CMML, six RARS, and 16 RA."	3.71	Thalidomide for the treatment of patients with myelodysplastic syndromes. ( Aivado, M; Gattermann, N; Germing, U; Haas, R; Misgeld, E; Strupp, C, 2002)
"Thalidomide was administered as a therapeutic agent for chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in a patient with breast cancer."	3.69	Thalidomide-induced perioral neuropathy. ( Elad, S; Galili, D; Garfunkel, AA; Or, R, 1997)
"Sensory neuropathies developed in three of four patients with prurigo nodularis who had been treated with thalidomide."	3.67	Thalidomide-induced peripheral neuropathy. Effect of serum factor on nerve cultures. ( Antel, J; Aronson, IK; Van den Broek, H; West, DP; Yu, R, 1984)
"Seven patients with prurigo nodularis and one with aphthous stomatitis were given 40-115 g of thalidomide for 1 to 6 years."	3.67	Development of polyneuropathy during thalidomide therapy. ( Asboe-Hansen, G; Brodthagen, H; Høyer, H; Wulff, CH, 1985)
" In routine practice, few patients received ixazomib-based induction therapy due to reasons including (1) patients' preference on oral regimens, (2) concerns on adverse events (AEs) of other intravenous/subcutaneous regimens, (3) requirements for less center visits, and (4) fears of COVID-19 and other infectious disease exposures."	2.94	Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study. ( Bao, L; Chen, B; Ding, K; Fu, C; Hua, L; Huang, Y; Li, B; Li, J; Liu, P; Luo, J; Wang, L; Wang, S; Wang, W; Wu, G; Xia, Z; Xu, T; Yang, W; Yang, Y; Zhang, W; Zhou, X, 2020)
"Thalidomide is an old well-known drug firstly used as morning sickness relief in pregnant women and then withdrawn from the market due to its severe side effects on fetal normal development."	2.82	Recent Advances in the Development of Thalidomide-Related Compounds as Anticancer Drugs. ( Barbarossa, A; Carocci, A; Franchini, C; Iacopetta, D; Sinicropi, MS, 2022)
"Thrombocytopenia was the most common grade ≥ 3 AE (35%)."	2.78	A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. ( Allietta, N; Angermund, R; Bladé, J; Blau, IW; Broer, E; Corradini, P; Dimopoulos, MA; Drach, J; Giraldo, P; Mitchell, V; Petrucci, MT; Teixeira, A, 2013)
" Nonhematologic grade 3/4 adverse events were reported in 35% of once-weekly patients and 51% of twice-weekly patients (P = ."	2.75	Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. ( Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Cavalli, M; Cavo, M; De Rosa, L; Evangelista, A; Falcone, AP; Gaidano, G; Gentili, S; Genuardi, M; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Liberati, AM; Musto, P; Nozzoli, C; Palumbo, A; Patriarca, F; Ria, R; Rizzo, V; Rossi, D, 2010)
"Disease progression was observed in 14 (45%) patients."	2.73	Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma. ( Amato, RJ; Malya, R; Rawat, A, 2008)
" Neuropathy is the main adverse effect, but appears to be cumulative dose-dependent, thus allowing long-term remission before drug suspension."	2.73	Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. ( Bradaschia, F; Lazzerini, M; Marchetti, F; Martelossi, S; Ronfani, L; Scabar, A; Ventura, A, 2007)
"Thalidomide was recently reintroduced to treat several immune-mediated pathologies."	2.73	Childhood thalidomide neuropathy: a clinical and neurophysiologic study. ( Alpigiani, MG; Buoncompagni, A; Calevo, MG; De Grandis, E; De Negri, E; Gandullia, P; Giribaldi, G; Grosso, P; Lamba, LD; Priolo, T; Veneselli, E; Viola, S, 2008)
"Significant peripheral neuropathy and deep vein thrombosis each occurred in only 3%."	2.72	A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ( Alsina, M; Anderson, KC; Blood, E; Dalton, WS; Desikan, KR; Doss, D; Freeman, A; Gorelik, S; Hideshima, T; Jagannath, S; Kelly-Colson, K; Knight, R; McKenney, ML; Mitsiades, CS; Munshi, NC; Olesnyckyj, M; Rajkumar, SV; Rich, R; Richardson, PG; Schlossman, RL; Warren, D; Weller, E; Wride, K; Wu, A; Zeldenrust, SR; Zeldis, J, 2006)
"Thalidomide was discontinued in 55 patients for lack of therapeutic response."	2.70	Thalidomide neuropathy in patients treated for metastatic prostate cancer. ( Culcea, E; Dahut, W; Figg, WD; Floeter, MK; Kruger, EA; Molloy, FM; Pluda, J; Reed, E; Sandbrink, F; Steinberg, SM; Syed, NA, 2001)
"Treatment continued until disease progression or unacceptable toxicity were encountered."	2.70	The treatment of advanced renal cell cancer with high-dose oral thalidomide. ( Ahern, R; Benson, C; Bridle, H; Eisen, T; Gore, ME; Mak, I; Pyle, L; Sapunar, F; Smalley, K; Stebbing, J, 2001)
"Thalidomide as a treatment for refractory IBD in children and adolescents can improve clinical remission and achieve longer-term maintenance of remission."	2.66	Thalidomide as a treatment for inflammatory bowel disease in children and adolescents: A systematic review. ( Cui, X; Li, H; Liu, C; Men, P; Qiu, T; Sun, T; Zhai, S, 2020)
" However, soon after their introduction into clinical practice, chemotherapy-induced peripheral neurotoxicity (CIPN) emerged as their main non-hematological and among dose-limiting adverse events."	2.61	Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment. ( Alberti, P; Argyriou, AA; Islam, B; Kolb, N; Lustberg, M; Staff, NP, 2019)
"Thalidomide is a known sensory neurotoxin in adults."	2.61	Thalidomide and neurotrophism. ( Bonar, SF; McCredie, J; O'Sullivan, DJ; Soper, JR; Willert, HG, 2019)
"Thalidomide has shown excellent results for severe cutaneous lupus erythematosus (CLE), but its prescription is limited by potentially severe adverse events."	2.58	Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis. ( Arnaud, L; Barbaud, A; Cesbron, E; Chasset, F; Francès, C; Tounsi, T, 2018)
"Although peripheral neuropathies in children are often of genetic origin, acquired causes should be carefully looked for and ruled out also in the pediatric age."	2.58	Peripheral neuropathy and gastroenterologic disorders: an overview on an underrecognized association. ( De' Angelis, GL; Di Mario, F; Fusco, C; Gaiani, F; Leandro, G; Pisani, F; Spagnoli, C, 2018)
"Multiple myeloma is a disease of the elderly, with about a third of patients at diagnosis older than 75 years of age."	2.53	Nuances in the Management of Older People With Multiple Myeloma. ( Ailawadhi, S; Gay, F; Larocca, A; Pawlyn, C; Roy, V, 2016)
"Recent developments in the treatment of multiple myeloma have led to improvements in response rates and to increased survival; however, relapse is inevitable in almost all patients."	2.52	Current treatment landscape for relapsed and/or refractory multiple myeloma. ( Anderson, KC; Dimopoulos, MA; Moreau, P; Richardson, PG, 2015)
" Treatment-specific tools and clinical assessments can be useful for optimizing dosing and schedule adjustments to increase therapy duration, and implementing supportive care strategies (e."	2.52	Treatment-related symptom management in patients with multiple myeloma: a review. ( Colson, K, 2015)
"Thalidomide is a synthetic glutamic acid derivative first introduced in 1956 in Germany as an over the counter medications."	2.50	[Current therapeutic indications of thalidomide and lenalidomide]. ( Cosiglio, FJ; Ordi-Ros, J, 2014)
"Patients with multiple myeloma aged older than 65 years have traditionally received an oral regimen combining melphalan and prednisone (MP)."	2.45	How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. ( Gay, F; Palumbo, A, 2009)
"Thalidomide has several mechanisms of action: several immuno-modulatory properties, an anti-angiogenic action and a hypnosedative effect."	2.43	[The revival of thalidomide: an old drug with new indications]. ( Laffitte, E, 2006)
" Depending on dosage and agent used symptoms resolve completely or not."	2.42	[Neurotoxic effects of medications: an update]. ( Arné-Bès, MC, 2004)
"Thalidomide was developed in the 1950s as a sedative having only a low toxicity."	2.42	[New pharmacological availability of thalidomide based on experience in patients with multiple myeloma]. ( Murakami, H, 2004)
"Thalidomide has immunomodulatory and anti-angiogenic properties which may underlie its activity in cancer."	2.41	Thalidomide in cancer. ( Mehta, J; Singhal, S, 2002)
"The incidence of multiple myeloma (MM) is two to three times higher in Black patients compared with other races, making it the most common hematologic malignancy in this patient population."	1.91	Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction. ( Cao, Y; Dhodapkar, M; Hall, KH; Harvey, RD; Hofmeister, CC; Joseph, NS; Kaufman, JL; Liu, Y; Lonial, S; Maples, KT; Nooka, AK; Sun, LF, 2023)
"Thalidomide levels were determined by high-performance liquid chromatography/tandem mass spectrometry."	1.62	One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels. ( Aikawa, NE; Arnone, M; Bonfa, E; Heise, CO; Kupa, LVK; Pasoto, SG; Pedrosa, TDN; Romiti, R; Silva, CAAD; Soares, R; Yuki, EFN, 2021)
"Thalidomide is an effective therapy in children with inflammatory bowel disease refractory to standard treatments, but thalidomide-induced peripheral neuropathy (TiPN) limits its long-term use."	1.46	Risk Factors and Outcomes of Thalidomide-induced Peripheral Neuropathy in a Pediatric Inflammatory Bowel Disease Cohort. ( Arrigo, S; Barp, J; Bramuzzo, M; Calvi, A; Carrozzi, M; Chicco, A; Costa, S; Decorti, G; Di Chio, T; Fontana, M; Ghione, S; Lanteri, P; Lazzerini, M; Lionetti, P; Lucafò, M; Magazzù, G; Maggiore, G; Martelossi, S; Montico, M; Pellegrin, MC; Pellegrino, S; Stocco, G; Udina, C; Ventura, A; Zuin, G, 2017)
" CIPN is a common dose limiting side effect in patients with MM."	1.46	The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry. ( Beijers, AJ; Eurelings, M; Minnema, MC; Mols, F; Oerlemans, S; van de Poll-Franse, LV; Vreugdenhil, A, 2017)
"Thalidomide was marketed for the treatment of morning sickness and resulted in foetal death and physical deformities."	1.39	Late-onset neurological symptoms in thalidomide-exposed subjects: a study of an Australasian cohort. ( Burke, D; Jankelowitz, SK; Spies, JM, 2013)
"We analyzed DNA from 1,495 patients with multiple myeloma."	1.37	Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. ( Child, JA; Corthals, SL; Davies, FE; Dickens, NJ; Durie, BG; Goldschmidt, H; Gregory, WM; Johnson, DC; Lokhorst, HM; Morgan, GJ; Ross, FM; Sonneveld, P; Van Ness, B; Walker, BA, 2011)
"Bortezomib has been shown to be highly active in MM patients with RI."	1.36	Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. ( Baldini, L; Boccadoro, M; Bringhen, S; Callea, V; Casulli, AF; Catalano, L; Cavo, M; Ciolli, S; Di Raimondo, F; Galimberti, S; Gentile, M; Mannina, D; Mele, G; Morabito, F; Musto, P; Offidani, M; Palmieri, S; Palumbo, A; Petrucci, MT; Pinotti, G; Piro, E; Tosi, P, 2010)
"Asthenia is the most common adverse effect of treatment, occurring in approximately 76% to 96% of patients receiving therapy."	1.36	Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. ( Anderson, K; Laubach, JP; Mitsiades, C; Richardson, PG; Schlossman, RL, 2010)
"Thalidomide effectively treats some dermatologic conditions that are refractory to standard medications."	1.35	A case series of 48 patients treated with thalidomide. ( Doherty, SD; Hsu, S, 2008)
" The threshold neurotoxic dosage is lower than previously reported."	1.35	Thalidomide and sensory neurotoxicity: a neurophysiological study. ( Arienti, S; Doria, A; Ermani, M; Rondinone, R; Zara, G, 2008)
"Nodular prurigo is characterized by nodules and papules that are intensely pruritic."	1.34	Peripheral neuropathy associated with nodular prurigo. ( Bharati, A; Wilson, NJ, 2007)
"Thalidomide is an anti-neoplastic agent with anti-angiogenic and other mechanisms of action."	1.34	Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma. ( Chan, P; Cheung, TT; Chok, SH; Epstein, RJ; Fan, ST; Lam, V; Ng, KK; Poon, RT; Wong, H; Yau, T, 2007)
"Thalidomide was withdrawn from world markets in 1961 following recognition of its teratogenic effects."	1.33	Thalidomide neuropathy in childhood. ( Chaitow, J; Darras, BT; Fleming, FJ; Jones, HR; Ryan, MM; Vytopil, M, 2005)
"Thalidomide has been reported as efficacious in refractory cutaneous lupus erythematosus (LE)."	1.33	Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients. ( Cardoso, CR; Coelho, A; de Souza Papi, JA; Salgado, DR; Schmal, TR; Souto, MI; Waddington Cruz, M, 2005)
"In experiment 1, rats with the neuritis but not those with the myositis developed neuropathic pain symptoms."	1.31	A neuroimmune interaction in painful peripheral neuropathy. ( Bennett, GJ, 2000)
" They were dosed at 43, 200 or 1000 mg/kg for 53 weeks followed by a 4-week treatment-free recovery period."	1.31	Lack of peripheral neuropathy in Beagle dogs after 53 weeks oral administration of thalidomide capsules. ( Allen, D; Brockman, M; Ehrhart, J; Evans, M; Morgan, M; Stirling, D; Teo, S; Thomas, S, 2000)
"Thalidomide is a potentially useful drug for several dermatological disorders."	1.31	Thalidomide usage in Wales: the need to follow guidelines. ( Chave, TA; Finlay, AY; Knight, AG, 2001)
" A correlation between total dosage and severeness of polyneuropathy could not be found."	1.26	[Electrophysiologic changes in thalidomide neuropathy in the treatment of discoid lupus erythematosus]. ( Ludolph, A; Matz, DR, 1982)

Research

Studies (190)

Authors

Clinical Trials (27)

Trial Overview

Trial Outcomes

Mean Neuropathy Severity Score (FACT-GOG-Ntx Total Score Assessment)

Timeframe	Studies, this research(%)	All Research%
pre-1990	32 (16.84)	18.7374
1990's	9 (4.74)	18.2507
2000's	69 (36.32)	29.6817
2010's	74 (38.95)	24.3611
2020's	6 (3.16)	2.80

Authors	Studies
Sun, LF	1
Maples, KT	1
Hall, KH	1
Liu, Y	2
Cao, Y	1
Joseph, NS	1
Hofmeister, CC	1
Kaufman, JL	1
Dhodapkar, M	1
Nooka, AK	1
Lonial, S	3
Harvey, RD	1
Islam, B	1
Lustberg, M	1
Staff, NP	1
Kolb, N	1
Alberti, P	1
Argyriou, AA	1
Qiu, T	1
Li, H	1
Sun, T	1
Men, P	1
Cui, X	1
Liu, C	1
Zhai, S	1
Li, J	1
Bao, L	1
Xia, Z	1
Wang, S	1
Zhou, X	1
Ding, K	1
Zhang, W	2
Yang, W	1
Li, B	1
Fu, C	1
Chen, B	1
Hua, L	1
Wang, L	1
Luo, J	1
Yang, Y	1
Xu, T	1
Wang, W	1
Huang, Y	1
Wu, G	1
Liu, P	1
Yuki, EFN	1
Soares, R	1
Kupa, LVK	1
Heise, CO	1
Aikawa, NE	1
Arnone, M	1
Romiti, R	1
Pedrosa, TDN	1
Silva, CAAD	1
Bonfa, E	1
Pasoto, SG	1
Barbarossa, A	1
Iacopetta, D	1
Sinicropi, MS	1
Franchini, C	1
Carocci, A	1
Nakazato, T	1
Hagihara, M	1
Sahara, N	1
Tamai, Y	1
Ishii, R	1
Tamaki, S	1
Wake, A	1
Tajika, K	1
Sakai, R	1
Kobayashi, T	1
Hua, J	1
Inoue, M	1
Aisa, Y	1
Fujisawa, S	1
Miyazaki, K	1
Irie, S	1
Tanaka, E	1
Higashihara, M	1
Holmberg, LA	1
Becker, PS	1
Bensinger, W	2
Aguiar, PM	1
de Mendonça Lima, T	1
Colleoni, GWB	1
Storpirtis, S	1
Kumar, S	2
Moreau, P	6
Hari, P	1
Mateos, MV	5
Ludwig, H	3
Shustik, C	1
Masszi, T	1
Spencer, A	1
Hájek, R	1
Romeril, K	1
Avivi, I	1
Liberati, AM	2
Minnema, MC	2
Einsele, H	2
Berg, D	1
Lin, J	1
Gupta, N	1
Esseltine, DL	1
Richardson, PG	5
Stino, AM	1
Efebera, Y	1
Al-Mayoof, O	1
Al Sughaiyer, H	1
Abuomar, W	1
Khan, M	1
Bramuzzo, M	1
Stocco, G	1
Montico, M	1
Arrigo, S	1
Calvi, A	1
Lanteri, P	1
Costa, S	1
Pellegrino, S	1
Magazzù, G	1
Barp, J	1
Ghione, S	1
Lionetti, P	1
Zuin, G	1
Fontana, M	1
Di Chio, T	1
Maggiore, G	1
Lazzerini, M	2
Lucafò, M	1
Udina, C	1
Pellegrin, MC	1
Chicco, A	1
Carrozzi, M	1
Decorti, G	1
Ventura, A	2
Martelossi, S	2
Chasset, F	1
Tounsi, T	1
Cesbron, E	1
Barbaud, A	1
Francès, C	1
Arnaud, L	1
Luczkowska, K	1
Litwinska, Z	1
Paczkowska, E	1
Machalinski, B	1
Kerckhove, N	1
Collin, A	1
Condé, S	1
Chaleteix, C	1
Pezet, D	1
Balayssac, D	1
Guastella, V	1
Soper, JR	1
Bonar, SF	1
O'Sullivan, DJ	3
McCredie, J	2
Willert, HG	1
Groenen, PS	1
van Helmond, N	1
Chapman, KB	1
Spagnoli, C	1
Pisani, F	1
Di Mario, F	1
Leandro, G	1
Gaiani, F	1
De' Angelis, GL	1
Fusco, C	1
Mlak, R	1
Szudy-Szczyrek, A	1
Mazurek, M	1
Szczyrek, M	1
Homa-Mlak, I	1
Mielnik, M	1
Chocholska, S	1
Jankowska-Łęcka, O	1
Małecka-Massalska, T	1
Hus, M	1
Kishimoto, S	1
Oshima, N	1
Rinker, M	1
Krishna, MC	1
Takebe, N	1
Briani, C	5
Torre, CD	1
Campagnolo, M	3
Lucchetta, M	2
Berno, T	3
Candiotto, L	1
Padua, L	1
Ermani, M	5
Cavaletti, G	4
Zambello, R	4
Ordi-Ros, J	1
Cosiglio, FJ	1
Katodritou, E	2
Vadikolia, C	1
Lalagianni, C	1
Kotsopoulou, M	1
Papageorgiou, G	1
Kyrtsonis, MC	2
Matsouka, P	1
Giannakoulas, N	1
Kyriakou, D	1
Karras, G	1
Anagnostopoulos, N	2
Michali, E	1
Briasoulis, E	1
Hatzimichael, E	1
Spanoudakis, E	1
Zikos, P	1
Tsakiridou, A	1
Tsionos, K	1
Anargyrou, K	1
Symeonidis, A	1
Maniatis, A	2
Terpos, E	3
Lazaryan, A	1
Hussein, MA	1
Reu, FJ	1
Faiman, B	1
Habecker, B	1
Ann Karam, M	1
Reed, J	1
Hamilton, K	1
Waksman, J	1
Bruening, K	1
Srkalovic, G	1
Andresen, S	1
Kalaycio, M	1
Sweetenham, JW	1
Sobecks, R	1
Dean, R	1
Knight, R	2
Zeldis, JB	2
Baz, R	1
Palumbo, A	8
Bringhen, S	3
Larocca, A	3
Rossi, D	2
Di Raimondo, F	2
Magarotto, V	1
Patriarca, F	2
Levi, A	2
Benevolo, G	2
Vincelli, ID	1
Grasso, M	2
Franceschini, L	1
Gottardi, D	1
Montefusco, V	2
Falcone, AP	2
Omedé, P	1
Marasca, R	1
Morabito, F	2
Mina, R	1
Guglielmelli, T	2
Nozzoli, C	2
Passera, R	1
Gaidano, G	2
Offidani, M	3
Ria, R	2
Petrucci, MT	4
Musto, P	3
Boccadoro, M	3
Cavo, M	8
Dimopoulos, MA	6
Leleu, X	1
Delforge, M	3
Morgan, GJ	2
Davies, FE	2
Sonneveld, P	4
Schey, SA	1
Zweegman, S	1
Hansson, M	1
Weisel, K	1
Facon, T	2
Miguel, JF	1
Lok, A	1
Mocquard, J	1
Bourcier, J	1
Redelsperger, L	1
Bonnet, A	1
Chauvin, C	1
Thomaré, P	1
Mahé, B	1
Touzeau, C	1
Garcia, MK	2
Cohen, L	1
Guo, Y	2
Zhou, Y	2
You, B	1
Chiang, J	2
Orlowski, RZ	1
Weber, D	2
Shah, J	1
Alexanian, R	1
Thomas, S	2
Romaguera, J	2
Zhang, L	1
Badillo, M	1
Chen, Y	1
Wei, Q	1
Lee, R	1
Delasalle, K	2
Green, V	1
Wang, M	2
Huang, H	1
Zhou, L	1
Peng, L	1
Fu, W	1
Zhang, C	1
Hou, J	1
Kamimura, T	1
Miyamoto, T	1
Yokota, N	1
Aoki, T	1
Ito, Y	1
Akashi, K	1
Tacchetti, P	3
Terragna, C	1
Galli, M	1
Zamagni, E	3
Pezzi, A	1
Martello, M	1
Tosi, P	4
Baldini, L	2
Peccatori, J	1
Ruggieri, M	1
Pantani, L	1
Lazzaro, A	1
Elice, F	1
Rocchi, S	1
Gozzetti, A	1
Koeppen, S	1
Chu, SH	1
Lee, YJ	1
Lee, ES	1
Geng, Y	1
Wang, XS	1
Cleeland, CS	1
Anyanwu, CO	1
Stewart, CL	1
Werth, VP	1
Shibayama, H	1
Anderson, KC	4
Colson, K	1
Ishida, T	2
Wang, Y	1
Yang, F	1
Shen, Y	1
Wang, J	3
Chang, VT	1
Andersson, BS	1
Qazilbash, MH	1
Champlin, RE	1
Berenson, JR	2
Guan, X	1
Wang, ML	1
Udd, KA	1
Vidisheva, A	1
Swift, RA	1
Spektor, TM	1
Bravin, E	1
Ibrahim, E	1
Treisman, J	1
Masri, M	1
Banach, M	1
Jurczyszyn, A	1
Skotnicki, A	1
Pawlyn, C	1
Gay, F	2
Roy, V	1
Ailawadhi, S	1
Nicotra, A	1
Newman, C	1
Johnson, M	1
Eremin, O	1
Friede, T	1
Malik, O	1
Nicholas, R	1
Castro, TB	1
Hallack Neto, AE	1
Atalla, A	1
Ribeiro, LC	1
Dalla Torre, C	1
Cacciavillani, M	1
Salvalaggio, A	1
De March, E	1
Barilà, G	1
Lico, A	1
Liew, WK	1
Pacak, CA	1
Visyak, N	1
Darras, BT	2
Bousvaros, A	1
Kang, PB	1
Pongcharoen, P	1
Fleischer, AB	2
García-Sanz, R	1
Corchete, LA	1
Alcoceba, M	1
Chillon, MC	1
Jiménez, C	1
Prieto, I	1
García-Álvarez, M	1
Puig, N	1
Rapado, I	1
Barrio, S	1
Oriol, A	2
Blanchard, MJ	1
de la Rubia, J	2
Martínez, R	1
Lahuerta, JJ	3
González Díaz, M	1
San Miguel, JF	1
Martínez-López, J	2
Sarasquete, ME	1
Popat, R	1
Brown, SR	1
Flanagan, L	1
Hall, A	1
Gregory, W	1
Kishore, B	1
Streetly, M	1
Oakervee, H	1
Yong, K	1
Cook, G	2
Low, E	1
Cavenagh, J	1
Rosiñol, L	1
Teruel, AI	1
de la Guía, AL	1
Blanchard, M	1
Granell, M	1
Sampol, M	1
Palomera, L	1
González, Y	1
Etxebeste, M	1
Martínez-Martínez, R	1
Hernández, MT	1
de Arriba, F	1
Alegre, A	1
Cibeira, M	1
Mateos, M	1
San Miguel, J	1
Bladé, J	4
Beijers, AJ	1
Oerlemans, S	1
Mols, F	1
Eurelings, M	1
Vreugdenhil, A	1
van de Poll-Franse, LV	1
Raza, S	1
Safyan, RA	1
Lentzsch, S	1
Amato, RJ	1
Malya, R	1
Rawat, A	1
von Lilienfeld-Toal, M	2
Hahn-Ast, C	1
Furkert, K	1
Hoffmann, F	2
Naumann, R	2
Bargou, R	1
Glasmacher, A	2
El-Cheikh, J	2
Stoppa, AM	1
Bouabdallah, R	1
de Lavallade, H	1
Coso, D	1
de Collela, JM	1
Auran-Schleinitz, T	1
Gastaut, JA	1
Blaise, D	1
Mohty, M	2
Doherty, SD	1
Hsu, S	1
Chaudhry, V	3
Cornblath, DR	1
Polydefkis, M	1
Ferguson, A	2
Borrello, I	2
Siniscalchi, A	1
Fratoni, S	1
Santeusanio, G	1
Del Poeta, G	1
de Fabritiis, P	1
Caravita, T	1
Cundari, S	1
Kocer, B	1
Sucak, G	1
Kuruoglu, R	1
Aki, Z	1
Haznedar, R	1
Erdogmus, NI	1
Prommer, EE	2
Chang, DZ	1
Lu, J	1
Yi, Q	1
Forman, A	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase I Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)[NCT00091624]	Phase 1	77 participants (Actual)	Interventional	2003-03-31	Completed
A PHASE III, MULTI-CENTER, RANDOMIZED OPEN LABEL STUDY OF VELCADE, MELPHALAN, PREDNISONE AND THALIDOMIDE (V-MPT) Versus VELCADE, MELPHALAN, PREDNISONE (V-MP) IN ELDERLY UNTREATED MULTIPLE MYELOMA PATIENTS[NCT01063179]	Phase 3	511 participants (Actual)	Interventional	2006-05-31	Completed
A Prospective, Observational Study, to Evaluate the Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for[NCT05218603]		100 participants (Anticipated)	Observational	2021-11-30	Recruiting
Multicenter Study of Pomalidomide, Cyclophosphamide, and Dexamethasone in Relapsed Refractory Myeloma: Safety Profile in Mexican Population[NCT03601624]	Phase 2	18 participants (Anticipated)	Interventional	2018-09-01	Recruiting
Acupuncture for Chemo-induced Peripheral Neuropathy in Multiple Myeloma and Lymphoma Patients[NCT00891618]	Phase 2	27 participants (Actual)	Interventional	2009-04-30	Completed
A Phase I/IIa Trial of VTD-panobinostat Treatment and Panobinostat Maintenance in Relapsed and Relapsed/Refractory Multiple Myeloma Patients[NCT02145715]	Phase 1/Phase 2	54 participants (Anticipated)	Interventional	2013-01-31	Active, not recruiting
A Prospective, Multicenter, Single Arm, Phase II Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone (BiRd Regimen) in the Treatment of the First Relapsed Multiple Myeloma[NCT04063189]	Phase 2	100 participants (Anticipated)	Interventional	2017-03-21	Recruiting
A Pilot Study on the Efficacy of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive by Next Generation Flow[NCT03992170]	Phase 2	50 participants (Anticipated)	Interventional	2018-12-31	Recruiting
VELCADE (Bortezomib) and Thalidomide in Newly Diagnosed Patients With Multiple Myeloma[NCT00287872]	Phase 2	30 participants (Actual)	Interventional	2004-09-30	Completed
Multicenter, Interventional, Single-arm, Phase IV Study Evaluating Tolerability of Eribulin and Its Relationship With a Set of Polymorphisms in an Unselected Population of Female Patients With Metastatic Breast Cancer[NCT02864030]	Phase 4	200 participants (Actual)	Interventional	2014-05-31	Completed
Evaluation of TNF-Alpha Modulator for Clinical and Molecular Indicators of Analgesic Effect[NCT00121563]	Phase 2	90 participants	Interventional	2005-07-31	Completed
Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431]	Phase 4	93 participants (Actual)	Interventional	2017-06-05	Completed
Phase I / II Study Of Carfilzomib (CFZ) Intensification Early After Autologous Transplantation (AHCT) For Plasma Cell Myeloma[NCT01658904]	Phase 1/Phase 2	3 participants (Actual)	Interventional	2012-07-31	Terminated (stopped due to study closed prematurely because investigator left National Institutes of Health)
Rapamycin-Resistant T Cell Therapy of Multiple Myeloma: Relapse Prevention and Relapse Therapy[NCT01239368]	Phase 1/Phase 2	34 participants (Actual)	Interventional	2010-11-10	Terminated (stopped due to Terminated due to insufficient accrual.)
Mobilization and Collection of Autologous Stem Cell for Transplantation (ASCT) for Plasma Cell Myeloma (PCM)[NCT01547806]	Phase 2	49 participants (Actual)	Interventional	2012-02-22	Completed
A National, Multi-Center, Open-Label Study of Velcade in Combination With Melphalan and Prednisone (V-MP) in Older Untreated Multiple Myeloma Patients.[NCT00388635]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2004-04-30	Completed
Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance[NCT01723839]	Phase 2	21 participants (Actual)	Interventional	2012-02-22	Completed
An Open-Label Study to Evaluate the Efficacy and Safety of Two CDC-501 Dose Regimens When Used Alone or in Combination With Dexamethasone for the Treatment Relapsed or Refractory Multiple Myeloma[NCT00044018]	Phase 2	102 participants (Actual)	Interventional	2002-04-01	Completed
A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone as Post Autologous Transplant Consolidation in Patients With High-risk Multiple Myeloma[NCT02906332]	Phase 2	12 participants (Actual)	Interventional	2016-12-12	Terminated (stopped due to FDA Hold Due to Updated Risks)
QUIREDEX: A National, Open-Label, Multicenter, Randomized, Phase III Study of Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression[NCT00480363]	Phase 3	120 participants (Actual)	Interventional	2007-05-31	Completed
A Phase I/II Study of Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Patients With Newly Diagnosed Transplant Eligible Multiple Myeloma[NCT05199311]	Phase 1/Phase 2	66 participants (Anticipated)	Interventional	2022-05-13	Recruiting
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma[NCT03702725]	Phase 1	14 participants (Actual)	Interventional	2019-08-29	Active, not recruiting
A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma[NCT04009109]	Phase 2	188 participants (Anticipated)	Interventional	2020-10-21	Recruiting
Randomized Controlled Double-blind Vs. Placebo Multicentre Study on the Safety and Effectiveness of Thalidomide in the Treatment of Refractory Crohn's Disease and Ulcerative Colitis.[NCT00720538]	Phase 3	84 participants (Actual)	Interventional	2008-08-31	Completed
Safety and Efficacy Assessments of Osalmid in the Treatment of Multiple Myeloma[NCT03670173]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2018-10-01	Active, not recruiting
A Double Blinded Randomized Crossover Phase III Study of Oral Thalidomide Versus Placebo in Patients With Stage D0 Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation[NCT00004635]	Phase 3	159 participants (Actual)	Interventional	2000-03-01	Completed
A Phase II Study of Peg-Interferon Alpha-2B (Peg-Intron(TM)) and Thalidomide in Adults With Recurrent High-Grade Gliomas[NCT00047879]	Phase 2	7 participants (Actual)	Interventional	2002-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"Functional Assessment of Cancer Treatment - Gynecologic Oncology Group Neurotoxicity Scale (FACT/GOG-Ntx) Version 4 used to assess efficacy of acupuncture for treatment-induced peripheral neuropathy among multiple myeloma and/or lymphoma patients. Severity of neuropathy measured by FACT-GOG-Ntx total score assessment where 11-item questionnaire 5 point rating scale (0=not at all and 4=equals very much). FACT/GOG-Ntx Total Score ranges from 0 (best possible outcome) to 44 (worst possible outcome)." (NCT00891618)
Timeframe: Baseline to Week 13. Assessments at baseline, once per week during the two treatment phases of the study, and one month (week 13) after the last acupuncture treatment.

Clinical Response to Treatment

Intervention	units on a scale (Mean)
	Baseline (n=19)	Week 4 (n=18)	Week 9 (n=15)	Week 13 (n=15)
Acupuncture	20.8	16.7	9.9	13.2

Clinical evaluations of disease response were determined with each cycle. Bone marrow biopsies were done at baseline and at study termination. Clinical responses were defined by the International Myeloma Working Group criteria: Stringent Complete Response (SCR), CR and normal free light chain ratio and no clonal cells in bone marrow; Complete Response (CR), Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; Very Good Partial Response (VGPR), Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours; Partial Response (PR), ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to < 200 mg/24 hours. Objective response is defined as a best overall response of SCR, CR, VGPR, or PR. (NCT00287872)
Timeframe: 1-6 months

Peripheral Motor and Sensory Neuropathy (Grade 2 and Higher)

Intervention	percentage of participants (Number)
Bortezomib and Thalidomide	81.5

Neuropathy was monitored using Total Neuropathy Score reduced (TNSr). (NCT00287872)
Timeframe: 1-6 months

The Time to Response

Serum Levels of Hydroxycloroquine

Serum Levels of Thalidomide

Intervention	participants (Number)
Bortezomib and Thalidomide	19

Intervention	months (Median)
Bortezomib and Thalidomide	2

Intervention	ng/mL (Mean)
Inactive SLE With Standard Dose of HCQ	991.6
Inactive SLE With Reduced Dose of HCQ	569.0

Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months

Engraftment Failure Transplant Related Mortality

Intervention	ng/mL (Mean)
SLE/Cutaneous Lupus With Thalidomide	415.1

Engraftment failure is defined as the failure to achieve neutrophil engraftment by day 21; defined from day 0, day of autologous hematopoietic cell transplantation (AHCT), as the first of three consecutive days on which the patient's absolute neutrophil count is greater than 0.5x10(9)/l following the nadir. Transplant related mortality is defined as any subject who dies in the first 100 days post-AHCT of any non-relapse related cause. (NCT01658904)
Timeframe: up to day 100

Number of Participants With Adverse Events

Intervention	participants (Number)
Cohort 1- CFZ 20 mg/m^2 (Day 1,2)	0

Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT01658904)
Timeframe: 8 months and 15 days

Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)

Intervention	participants (Number)
Cohort 1- CFZ 20 mg/m^2 (Day 1,2)	1

Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01239368)
Timeframe: Date treatment consent signed to last date off study, 81 months and 6 days

Number of Participants With Progression Free Survival in Cohort A Th1 (Type 1 T Helper Cells)/Tc1 (T Cytotoxic Cells, Type 1) Rapa Prevention of Relapse

Intervention	Participants (Count of Participants)
Cohort 1 - 1x10(5) T Cells/kg	1
Cohort 2 - 5x10(5) T Cells/kg	1
Cohort 3 - 1x10(6) T Cells/kg	1
Cohort 4 - 3x10(6) T Cells/kg	2
Cohort 5 - 5x10(6) T Cells/kg	5
Cohort 5B - 5x10(6) T Cells/kg	2
Cohort 6 - 15x10(6) T Cells/kg	3
Cohort 7 - 45x10(6) T Cells/kg	0
Cohort A - Th1/Tc1.Rapa Prevention of Relapse	1
Cohort B - Th1/Tc1.Rapa for Relapsed Multiple Myeloma	4

Progressive disease is assessed by the Consensus of the International Myeloma Working Group criteria and is defined as one or more of the following: Increases of greater or equal to 25% in serum M-component (minimum absolute increase of 0.5 g/dl) or urine M-component (minimum absolute increase of 200mg/24h) or percentage of bone marrow plasma cells (minimum absolute percentage of 10%) or size of bone lesions or new plasmacytoma, or development of hypercalcemia solely attributable to the disease. (NCT01239368)
Timeframe: Study completion at 22 months

Number of Patients Who Developed a Partial Response (PR)+Complete Response (CR) in Cohort B at Any Time Point Post Therapy With PR/CR Being Maintained Until Study Completed

Intervention	Participants (Count of Participants)
Cohort A - Th1/Tc1.Rapa Prevention of Relapse	1

Patients whose tumors shrunk and were disease free after therapy in cohort B. Partial response and complete response were assessed by the Consensus of the International Myeloma Working Group criteria. Partial response is defined as 50% or greater reduction in serum M-protein and 90% or greater reduction in 24-h urinary M-protein (or to less than 200 mg per 24h), 50% or greater reduction in the size of soft tissue plasmacytomas, if present at baseline, no evidence of progressive or new bone lesions if radiographic studies were performed (X-rays not required in absence of clinical indication). Complete response is defined as negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and 5% or less plasma cells in bone marrow and no evidence of progressive or new bone lesion if radiographic studies were performed. Progressive disease is increases of ≥25% in serum M-component/urine M-component, or size of bone lesions. (NCT01239368)
Timeframe: Study completion at 22 months

Number of Patients With an Adverse Event Attributable to the Investigational Therapy

Intervention	Participants (Count of Participants)
Cohort B - Th1/Tc1.Rapa for Relapsed Multiple Myeloma	2

Participants were assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0) (NCT01239368)
Timeframe: 2 months

Average Number of Cluster of Differentiation 34 (CD34) Cells Collected (Per kg Recipient Body Weight (BW))

Intervention	Participants (Count of Participants)
Cohort 1 - 1x10(5) T Cells/kg	0
Cohort 2 - 5x10(5) T Cells/kg	0
Cohort 3 - 1x10(6) T Cells/kg	0
Cohort 4 - 3x10(6) T Cells/kg	0
Cohort 5 - 5x10(6) T Cells/kg	0
Cohort 5B - - 5x10(6) T Cells/kg	0
Cohort 6 - 15x10(6) T Cells/kg	0
Cohort 7- 45x10(6) T Cells/kg	0
Cohort A - Th1/Tc1.Rapa Prevention of Relapse	0
Cohort B - Th1/Tc1.Rapa Prevention of Relapse	0

Progenitor cells by apheresis was determined by flow cytometry. (NCT01547806)
Timeframe: Through Day 2 of collection

Median and Standard Deviation of Cluster of Differentiation 34 (CD34) Cells Collected (Per Kg Recipient Body Weight) (BW)

Intervention	Number of CD34 cells per kg/BW (x 10EE6) (Mean)
Hematopoietic Progenitor Cells	6.4

Progenitor cells by apheresis was determined by flow cytometry. (NCT01547806)
Timeframe: Through Day 2 of collection

Number of Hematopoietic Progenitor Cell (HPC) Apheresis Products Collected and Cryopreserved for Subsequent Use in Autologous Hematopoietic Cell Transplantation (AHCT) in Subjects With Plasma Cell Myeloma (PCM)

Intervention	Number of CD34 cells per kg/BW (x 10EE6) (Median)
Hematopoietic Progenitor Cells	6.3

The cryopreserved stem cells are stored under Good Manufacturing Practice (GMP) conditions in the National Institutes of Health (NIH) Department of Transfusion Medicine until a referring physician requests the products for standard clinical care. (NCT01547806)
Timeframe: Indefinitely until a referring physician requests the product for standard clinical care or until product(s) is no longer needed and disposed of

Number of Participants With Serious and Non-Serious Adverse Events

Intervention	products (Number)
Hematopoietic Progenitor Cells (HPC)	49

Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01547806)
Timeframe: 27 months and 27 days

Percentage of Patients Achieving at Least 2 x 10^6 Cluster of Differentiation 34 (CD34) Cells Per Kg Recipient Body Weight on Day 1 of Apheresis

Intervention	Participants (Count of Participants)
Hematopoietic Progenitor Cells (HPC)	16

Progenitor cells by apheresis was determined by flow cytometry. The stated goal was a minimum dose of 2x10EE^6/kg following apheresis. (NCT01547806)
Timeframe: Day 1 of apheresis

Percentage of Patients Requiring 2 Days to Achieve at Least 2 x 10^6 Cluster of Differentiation 34 (CD34) Cells Per Kg Recipient Body Weight

Intervention	percentage of patients (Number)
Hematopoietic Progenitor Cells (HPC)	98

Progenitor cells by apheresis was determined by flow cytometry. (NCT01547806)
Timeframe: Through Day 2 of collection

Percentage of Patients That Achieved ≥ 2 x 10^6 But Less Than 5 x 10^6 Cluster of Differentiation 34 (CD34) Cells/kg (Day One Collection)

Intervention	percentage of patients (Number)
Hematopoietic Progenitor Cells	2

Percentage of patents achieving collecting the minimum but not optimal CD34 cell number. (NCT01547806)
Timeframe: Day one of collection

Range of Cluster of Differentiation 34 (CD34) Cells Collected

Intervention	percentage of patients (Number)
Hematopoietic Progenitor Cells	31

Progenitor cells by apheresis was determined by flow cytometry. (NCT01547806)
Timeframe: Through Day 2 of collection

25th and 75th Percentile Values of Cluster of Differentiation 34 (CD34) Cells Collected

Intervention	Number of CD34 cells per kg/BW (x 10EE6) (Median)
Hematopoietic Progenitor Cells	6.3

Progenitor cells by apheresis was determined by flow cytometry. (NCT01547806)
Timeframe: Through Day 2 of collection

Percentage of Patients That Achieved or Did Not Achieve 5 x 10^6 Cluster of Differentiation 34 (CD34) Cells/kg

Intervention	Number of CD34 cells per kg/BW (x 10EE6) (Number)
	25th percentile	75th percentile
Hematopoietic Progenitor Cells	4.0	8.0

Here is the percentage of patients that achieved or did not achieve 5 x 10^6 CD34 cells/kg in a single apheresis. (NCT01547806)
Timeframe: Through Day 2 of collection

Percentage of Patients That Required Plerixafor + Granulocyte-colony Stimulating Factor (G-CSF) And Only G-CSF (no Plerixafor)

Intervention	percentage of patients (Number)
	Achieved 5 x 10EE CD34 cells/kg	Did not achieve 5 x 10EE CD34 cells/kg
Hematopoietic Progenitor Cells	65	35

Percentage of patients that required Plerixafor injection in addition to G-CSF mobilization or none at all (NCT01547806)
Timeframe: One week of mobilization therapy

Complete Response

Intervention	percentage of patients (Number)
	Plerixafor + G-CSF	Only G-CSF (no plerixafor)
Hematopoietic Progenitor Cells	47	53

Analysis of the Primary Endpoint: The complete responses will be estimated by the number of patients with CR divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 4 cycles

Overall Response Rate

Intervention	Percentage of Participants (Number)
FCR With Lenalidomide	45

Analysis of the other Secondary Endpoints: The overall response rate will be estimated by the number of patients with complete and partial responses divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 6 cycles

Evaluation of Stringent Complete Response, Complete Response, and Very Good Partial Response Rate (sCR + CR + VGPR Rate).

Intervention	Percentage of Participants (Number)
FCR With Lenalidomide	95

Assessed by the investigator per International Myeloma Working Group criteria(IMWG) uniform response criteria. Result reflects number of participants whose best overall response qualified as sCR, CR, or VGPR in 2 year follow up period. (NCT02906332)
Timeframe: Every 3 weeks (day 1 of every 21-day treatment cycle +/- 7 days) through 12 weeks.

Number of Participants Serious Adverse Events

Intervention	Participants (Count of Participants)
Pembrolizumab + Lenalidomide	11

Safety will be assessed by quantifying the toxicities and grades experienced by subjects who have received pembrolizumab (MK-3475), lenalidomide and dexamethasone, including serious adverse events (SAEs). Result reflects count of participants who experienced an SAE. (NCT02906332)
Timeframe: Up to 3 years

Number of Participants Who Progressed at 12 Months

Intervention	Participants (Count of Participants)
Pembrolizumab + Lenalidomide	1

Assessed at 12 months; Subjects without documented PD or death will be censored at the last disease assessment date. Those who died without documented PD will be censored at the time of death. Result reflects count of participants who had progressed at 12 months. (NCT02906332)
Timeframe: Time from Day 0 (transplant) and date of enrollment to study completion (through 12 weeks) by investigator assessment.

Progression Free Survival (PFS)

Intervention	Participants (Count of Participants)
Pembrolizumab + Lenalidomide	10

PFS will be assessed from the date of ASCT, with day 0 defined as date of stem cell infusion (if tandem transplant the 2nd of 2 transplants will be used) until the date of progression, defined as the date at which the patient starts the next line of therapy or the date of death. (NCT02906332)
Timeframe: Up to 3 years

The Number of Participants With Adverse Events

Intervention	months (Median)
Pembrolizumab + Lenalidomide	27.6

Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00004635)
Timeframe: Date treatment consent signed to date off study, approximately 60 months

Time to Progression

Intervention	Participants (Count of Participants)
Thalidomide	117
Placebo	98

Time to progression is defined as follows: if the PSA returns to baseline (defined as the PSA value prior to starting leuprolide or goserelin) or increases to the absolute value of 5 ng/ml. (NCT00004635)
Timeframe: 36 months

The Number of Participants With Adverse Events

Intervention	months (Median)
Thalidomide	15
Placebo	9.6

Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00047879)
Timeframe: 4 months

Article	Year
Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment. Journal of the peripheral nervous system : JPNS, 2019, Volume: 24 Suppl 2 Topics: Antineoplastic Agents; Cohort Studies; Furans; Humans; Immunosuppressive Agents; Ketones; Neoplasms;	2019
Thalidomide as a treatment for inflammatory bowel disease in children and adolescents: A systematic review. Journal of clinical pharmacy and therapeutics, 2020, Volume: 45, Issue:5 Topics: Adolescent; Child; Colitis, Ulcerative; Crohn Disease; Dose-Response Relationship, Drug; Humans; Imm	2020
Recent Advances in the Development of Thalidomide-Related Compounds as Anticancer Drugs. Current medicinal chemistry, 2022, Volume: 29, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Female; Humans; Multiple Myeloma; Peripheral Nervous	2022
Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses. Critical reviews in oncology/hematology, 2017, Volume: 113 Topics: Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Thalidomide	2017
Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2018, Volume: 78, Issue:2 Topics: Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Peripheral Nervous System Diseases	2018
Pathophysiology of drug-induce peripheral neuropathy in patients with multiple myeloma. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2018, Volume: 69, Issue:2 Topics: Animals; Antineoplastic Agents; Bortezomib; Humans; MicroRNAs; Multiple Myeloma; Nerve Growth Factor	2018
[Chemotherapy-induced peripheral neuropathy: Symptomatology and epidemiology]. Bulletin du cancer, 2018, Volume: 105, Issue:11 Topics: Antineoplastic Agents; Bortezomib; Humans; Immunosuppressive Agents; Neoplasms; Peripheral Nervous S	2018
Thalidomide and neurotrophism. Skeletal radiology, 2019, Volume: 48, Issue:4 Topics: Abnormalities, Drug-Induced; Extremities; Humans; Infant, Newborn; Limb Deformities, Congenital; Per	2019
Peripheral neuropathy and gastroenterologic disorders: an overview on an underrecognized association. Acta bio-medica : Atenei Parmensis, 2018, 12-17, Volume: 89, Issue:9-S Topics: Antibodies, Monoclonal; Antirheumatic Agents; Campylobacter Infections; Celiac Disease; Child; Comor	2018
[Current therapeutic indications of thalidomide and lenalidomide]. Medicina clinica, 2014, Apr-22, Volume: 142, Issue:8 Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents; Antineoplastic Agents; Collagen Diseases; End	2014
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia, 2014, Volume: 28, Issue:8 Topics: Age Factors; Clinical Trials as Topic; Dexamethasone; Drug Administration Schedule; Humans; Immunolo	2014
Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials. Leukemia research, 2014, Volume: 38, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II	2014
Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy. Oncology research and treatment, 2014, Volume: 37, Issue:9 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationshi	2014
Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015, Volume: 23, Issue:2 Topics: Amitriptyline; Anticonvulsants; Antidepressive Agents; Antineoplastic Agents; Boronic Acids; Bortezo	2015
[Supportive care in multiple myeloma for continuing anti-myeloma therapies]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10 Topics: Anemia; Bone Density Conservation Agents; Bone Diseases, Metabolic; Boronic Acids; Bortezomib; Dipho	2014
Current treatment landscape for relapsed and/or refractory multiple myeloma. Nature reviews. Clinical oncology, 2015, Volume: 12, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell T	2015
Treatment-related symptom management in patients with multiple myeloma: a review. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015, Volume: 23, Issue:5 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; H	2015
Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. Journal of the National Cancer Institute, 2016, Volume: 108, Issue:3 Topics: Disease-Free Survival; Humans; Immunosuppressive Agents; Infections; Lenalidomide; Maintenance Chemo	2016
Nuances in the Management of Older People With Multiple Myeloma. Current hematologic malignancy reports, 2016, Volume: 11, Issue:3 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Dexamethasone;	2016
Itch Management: Systemic Agents. Current problems in dermatology, 2016, Volume: 50 Topics: Amines; Analgesics; Analgesics, Opioid; Anion Exchange Resins; Antidepressive Agents; Aprepitant; Ch	2016
Immunomodulatory Drugs (IMiDs) in Multiple Myeloma. Current cancer drug targets, 2017, Volume: 17, Issue:9 Topics: Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peripheral Ne	2017
A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. European journal of haematology, 2008, Volume: 81, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Constipation; De	2008
Thalidomide chemotherapy-induced peripheral neuropathy: actual status and new perspectives with thalidomide analogues derivatives. Mini reviews in medicinal chemistry, 2009, Volume: 9, Issue:7 Topics: Animals; Clinical Trials as Topic; Humans; Hydrolysis; Immunosuppressive Agents; Peripheral Nervous	2009
Palliative oncology: thalidomide. The American journal of hospice & palliative care, 2010, Volume: 27, Issue:3 Topics: Angiogenesis Inhibitors; Constipation; Cytokines; Drug Eruptions; Humans; Hydrolysis; Hypotension, O	2010
Multiple myeloma, painful neuropathy, acupuncture? American journal of clinical oncology, 2009, Volume: 32, Issue:3 Topics: Acupuncture Therapy; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Mye	2009
How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. Hematology. American Society of Hematology. Education Program, 2009 Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Prot	2009
Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica, 2010, Volume: 95, Issue:2 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous Syste	2010
Management of treatment-related adverse events in patients with multiple myeloma. Cancer treatment reviews, 2010, Volume: 36 Suppl 2 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disorders of Excessive Somnolence; Gastrointestina	2010
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. The Lancet. Oncology, 2010, Volume: 11, Issue:11 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Incidence; Multiple Myeloma; Peripheral Ne	2010
Thalidomide. Journal of pain and symptom management, 2011, Volume: 41, Issue:1 Topics: Abnormalities, Drug-Induced; Cardiovascular Diseases; Chronic Disease; Dose-Response Relationship, D	2011
Multiple myeloma. Annual review of medicine, 2011, Volume: 62 Topics: Anemia; Bone Diseases; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Proteinase Inhi	2011
Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia, 2012, Volume: 26, Issue:4 Topics: Boronic Acids; Bortezomib; Early Diagnosis; Humans; Immunologic Factors; Incidence; Multiple Myeloma	2012
[Multiple myeloma]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot	2012
Treatment of prurigo nodularis with thalidomide: a case report and review of the literature. International journal of dermatology, 2003, Volume: 42, Issue:5 Topics: Adult; Dermatologic Agents; Extremities; Humans; Male; Peripheral Nervous System Diseases; Prurigo;	2003
[Neurotoxic effects of medications: an update]. Revue medicale de Liege, 2004, Volume: 59 Suppl 1 Topics: Anti-Retroviral Agents; Antineoplastic Agents; Carboplatin; Cisplatin; Colchicine; Docetaxel; Humans	2004
Adverse effects of thalidomide administration in patients with neoplastic diseases. The American journal of medicine, 2004, Oct-01, Volume: 117, Issue:7 Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials, Phase II	2004
Chemotherapy-induced peripheral neurotoxicity. Expert opinion on drug safety, 2004, Volume: 3, Issue:6 Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Epothilones; Humans; Neoplasms; Neuroprote	2004
[New pharmacological availability of thalidomide based on experience in patients with multiple myeloma]. Nihon Hansenbyo Gakkai zasshi = Japanese journal of leprosy : official organ of the Japanese Leprosy Association, 2004, Volume: 73, Issue:3 Topics: Animals; Blood Vessels; Clinical Trials, Phase II as Topic; Ectromelia; Erythema Nodosum; Female; Hu	2004
Toxic neuropathy. Current opinion in neurology, 2005, Volume: 18, Issue:5 Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Epothilones; Genetic Therapy; Humans;	2005
A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. British journal of haematology, 2006, Volume: 132, Issue:5 Topics: Clinical Trials, Phase II as Topic; Data Collection; Dose-Response Relationship, Drug; Drug Administ	2006
Advances in understanding drug-induced neuropathies. Drug safety, 2006, Volume: 29, Issue:1 Topics: Antineoplastic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Age	2006
[The revival of thalidomide: an old drug with new indications]. La Revue du praticien, 2006, Nov-30, Volume: 56, Issue:18 Topics: Angiogenesis Inhibitors; Drug Eruptions; Humans; Leprostatic Agents; Peripheral Nervous System Disea	2006
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer, 2007, Sep-01, Volume: 110, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol	2007
[Adverse effects of therapeutic drugs on peripheral nervous system]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2007, Aug-10, Volume: 96, Issue:8 Topics: Anti-HIV Agents; Anticonvulsants; Antineoplastic Agents; Antitubercular Agents; Cisplatin; Dose-Resp	2007
Thalidomide therapy for inflammatory dermatoses. International journal of dermatology, 1984, Volume: 23, Issue:9 Topics: Abnormalities, Drug-Induced; Adult; Animals; Chemical Phenomena; Chemistry; Female; Humans; Immunity	1984
Bangkok Workshop on Leprosy Research. Treatment of reactions and nerve damage. International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association, 1996, Volume: 64, Issue:4 Suppl Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Clofazimine; Cyclosporine; Drug A	1996
Thalidomide: current and potential clinical applications. The American journal of medicine, 2000, Apr-15, Volume: 108, Issue:6 Topics: Angiogenesis Inhibitors; Anti-HIV Agents; Arthritis, Rheumatoid; Behcet Syndrome; Dermatologic Agent	2000
Thalidomide in cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2002, Volume: 56, Issue:1 Topics: Angiogenesis Inhibitors; Bradycardia; Exanthema; Humans; Interleukin-2; Interleukin-6; Neoplasms; Pe	2002
The morphological basis for alterations in nerve conduction in peripheral neuropathy. Proceedings of the Royal Society of Medicine, 1971, Volume: 64, Issue:3 Topics: Amyloidosis; Animals; Axons; Beriberi; Cresols; Demyelinating Diseases; Diabetic Neuropathies; Diffu	1971
Summary of recent abstracts. 8. Leprosy. Tropical diseases bulletin, 1970, Volume: 67, Issue:9 Topics: Animals; Antibody Formation; BCG Vaccine; Dapsone; Disease Models, Animal; Guinea Pigs; Humans; Lepr	1970
[Side effects of drugs. 4. Drug induced polyneuropathies and myopathies]. Lakartidningen, 1969, Dec-15, Volume: 66 Topics: Adrenocorticotropic Hormone; Chloroquine; Glucocorticoids; Humans; Hydralazine; Isoniazid; Muscular	1969
Peripheral neuropathy caused by chemical agents. CRC critical reviews in toxicology, 1973, Volume: 2, Issue:3 Topics: Acrylamides; Animals; Arsenic; Axons; Carbon Disulfide; Disulfiram; Humans; In Vitro Techniques; Iso	1973

Article	Year
Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study. Annals of hematology, 2020, Volume: 99, Issue:11 Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bor	2020
Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma. Annals of hematology, 2021, Volume: 100, Issue:11 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamid	2021
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. British journal of haematology, 2017, Volume: 178, Issue:4 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols	2017
Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma. American journal of hematology, 2014, Volume: 89, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th	2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-01, Volume: 32, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free	2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-01, Volume: 32, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free	2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-01, Volume: 32, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free	2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-01, Volume: 32, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free	2014
Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. Journal of hematology & oncology, 2014, May-09, Volume: 7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Electroacupuncture;	2014
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. American journal of hematology, 2014, Volume: 89, Issue:12 Topics: Actin Cytoskeleton; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axons;	2014
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. The Lancet. Haematology, 2016, Volume: 3, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr	2016
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. The Lancet. Haematology, 2016, Volume: 3, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr	2016
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. The Lancet. Haematology, 2016, Volume: 3, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr	2016
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. The Lancet. Haematology, 2016, Volume: 3, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr	2016
Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial. Leukemia, 2017, Volume: 31, Issue:9 Topics: Bortezomib; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Interfer	2017
Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma. American journal of clinical oncology, 2008, Volume: 31, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Constipation; Di	2008
A prospective double-blind, placebo-controlled study of thalidomide sensory symptoms in an elderly population with age-related macular degeneration. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2010, Volume: 17, Issue:5 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Double-Blind Met	2010
Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. American journal of hematology, 2010, Volume: 85, Issue:10 Topics: Aged; Antineoplastic Agents; Constipation; Disease Progression; Disease-Free Survival; Drug Administ	2010
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood, 2010, Dec-02, Volume: 116, Issue:23 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Surviv	2010
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood, 2010, Dec-02, Volume: 116, Issue:23 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Surviv	2010
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood, 2010, Dec-02, Volume: 116, Issue:23 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Surviv	2010
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood, 2010, Dec-02, Volume: 116, Issue:23 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Surviv	2010
Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma. British journal of haematology, 2011, Volume: 152, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte	2011
A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. British journal of haematology, 2013, Volume: 160, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol	2013
Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. The Journal of investigative dermatology, 2002, Volume: 119, Issue:5 Topics: Adult; Dermatologic Agents; Female; Humans; Incidence; Male; Middle Aged; Neurotoxins; Peripheral Ne	2002
Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1. Neurology, 2003, Jan-14, Volume: 60, Issue:1 Topics: Adolescent; Adult; Angiogenesis Inhibitors; Child; Cohort Studies; Dermatologic Agents; Dose-Respons	2003
An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. British journal of cancer, 2003, Mar-24, Volume: 88, Issue:6 Topics: Aged; Aged, 80 and over; Androgens; Angiogenesis Inhibitors; Disease Progression; Endothelial Growth	2003
Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. European journal of haematology, 2004, Volume: 72, Issue:6 Topics: Aged; Aged, 80 and over; Constipation; Disorders of Excessive Somnolence; Dose-Response Relationship	2004
Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. Archives of dermatology, 2004, Volume: 140, Issue:7 Topics: Administration, Oral; Adult; Aged; Drug Administration Schedule; Female; HIV Infections; Humans; Imm	2004
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. European journal of haematology, 2005, Volume: 74, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh	2005
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. European journal of haematology, 2005, Volume: 74, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh	2005
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. European journal of haematology, 2005, Volume: 74, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh	2005
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. European journal of haematology, 2005, Volume: 74, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh	2005
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. European journal of haematology, 2005, Volume: 74, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh	2005
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. European journal of haematology, 2005, Volume: 74, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh	2005
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. European journal of haematology, 2005, Volume: 74, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh	2005
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. European journal of haematology, 2005, Volume: 74, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh	2005
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. European journal of haematology, 2005, Volume: 74, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh	2005
Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica, 2006, Volume: 91, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free	2006
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:2 Topics: Adult; Aged; Angiogenesis Inhibitors; Area Under Curve; Asthenia; Dose-Response Relationship, Drug;	2007
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Sep-20, Volume: 24, Issue:27 Topics: Aged; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Electrophysiology; Female; Humans;	2006
Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. Alimentary pharmacology & therapeutics, 2007, Feb-15, Volume: 25, Issue:4 Topics: Adolescent; Colitis, Ulcerative; Crohn Disease; Drug Administration Schedule; Female; Humans; Male;	2007
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer, 2007, Sep-01, Volume: 110, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol	2007
Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. European journal of haematology, 2007, Volume: 79, Issue:3 Topics: Adult; Aged; Dexamethasone; Dose-Response Relationship, Drug; Female; Humans; Leukopenia; Male; Midd	2007
Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology, 2007, Aug-07, Volume: 69, Issue:6 Topics: Action Potentials; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Female; Follow-Up St	2007
Childhood thalidomide neuropathy: a clinical and neurophysiologic study. Pediatric neurology, 2008, Volume: 38, Issue:3 Topics: Action Potentials; Adolescent; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Immunosup	2008
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:4 Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Chemotherapy, Adjuvant; Combined Modality T	2000
Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle & nerve, 2001, Volume: 24, Issue:8 Topics: Action Potentials; Age Factors; Aged; Aged, 80 and over; Brachial Plexus; Cohort Studies; Dose-Respo	2001
The treatment of advanced renal cell cancer with high-dose oral thalidomide. British journal of cancer, 2001, Sep-28, Volume: 85, Issue:7 Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Constipation; Cyt	2001

Article	Year
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction. JCO oncology practice, 2023, Volume: 19, Issue:9 Topics: Black or African American; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous Sy	2023
One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels. Lupus, 2021, Volume: 30, Issue:6 Topics: Adult; Female; Humans; Incidence; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Mal	2021
Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin. Acta haematologica, 2017, Volume: 137, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Combined Modality Therapy; Con	2017
Lenalidomide-responsive anti-myelin-associated glycoprotein neuropathy. Muscle & nerve, 2017, Volume: 56, Issue:4 Topics: Aged; Female; Humans; Immunoglobulin M; Lenalidomide; Myelin-Associated Glycoprotein; Peripheral Ner	2017
POEMS syndrome: a rare cause of exudative ascites and chronic peripheral neuropathy. BMJ case reports, 2017, Jun-20, Volume: 2017 Topics: Adult; Ascites; Dexamethasone; Humans; Lenalidomide; Male; Myeloma Proteins; Paraproteinemias; Perip	2017
Risk Factors and Outcomes of Thalidomide-induced Peripheral Neuropathy in a Pediatric Inflammatory Bowel Disease Cohort. Inflammatory bowel diseases, 2017, Volume: 23, Issue:10 Topics: Adolescent; Child; Female; Humans; Inflammatory Bowel Diseases; Intercellular Adhesion Molecule-1; I	2017
Chemotherapy-Induced Peripheral Neuropathy Treated with Dorsal Root Ganglion Stimulation. Pain medicine (Malden, Mass.), 2019, 04-01, Volume: 20, Issue:4 Topics: Electric Stimulation Therapy; Female; Ganglia, Spinal; Humans; Immunosuppressive Agents; Lupus Eryth	2019
Polymorphisms in the promotor region of the CRBN gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients. British journal of haematology, 2019, Volume: 186, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Female; Genetic Predisposition to Disease; Humans; Immunosuppressive	2019
Identification of high-risk drugs related to chemotherapy-induced peripheral neuropathy in Cancer Therapy Evaluation Program-sponsored phase I trials. European journal of cancer (Oxford, England : 1990), 2019, Volume: 115 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Angiogenesis Inhibitors; An	2019
Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single-centre prospective study. Journal of the peripheral nervous system : JPNS, 2013, Volume: 18, Issue:1 Topics: Adult; Aged; Angiogenesis Inhibitors; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myel	2013
"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. Annals of hematology, 2014, Volume: 93, Issue:1 Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dex	2014
Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma. Haematologica, 2014, Volume: 99, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason	2014
Peripheral neuropathy exacerbated by lenalidomide in a patient with multiple myeloma. Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:15 Topics: Fatal Outcome; Humans; Immunologic Factors; Leg; Lenalidomide; Male; Middle Aged; Multiple Myeloma;	2014
Thalidomide-induced orofacial neuropathy. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2014, Volume: 20, Issue:7 Topics: Adult; Face; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Paresthesia;	2014
[Complications and managements in treatment of melphalan, prednisone and new agents]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Molecu	2015
Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016, Volume: 24, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Per	2016
[Thalidomide induced peripheral neuropathy in multiple myeloma patients]. Przeglad lekarski, 2015, Volume: 72, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carpal Tunnel Syndrome; Female; Humans; Male;	2015
Peripheral Nerve Dysfunction in Middle-Aged Subjects Born with Thalidomide Embryopathy. PloS one, 2016, Volume: 11, Issue:4 Topics: Abnormalities, Multiple; Adult; Case-Control Studies; Female; Humans; Male; Middle Aged; Nerve Fiber	2016
Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2016, Volume: 49, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol	2016
Lenalidomide long-term neurotoxicity: Clinical and neurophysiologic prospective study. Neurology, 2016, Sep-13, Volume: 87, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Drug Resi	2016
Longitudinal Patterns of Thalidomide Neuropathy in Children and Adolescents. The Journal of pediatrics, 2016, Volume: 178 Topics: Adolescent; Child; Crohn Disease; Female; Humans; Immunosuppressive Agents; Longitudinal Studies; Ma	2016
Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array. Hematological oncology, 2017, Volume: 35, Issue:4 Topics: Bortezomib; Female; Genotype; Humans; Male; Multiple Myeloma; Peripheral Nervous System Diseases; Po	2017
The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry. Annals of hematology, 2017, Volume: 96, Issue:4 Topics: Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Mu	2017
Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma. Clinical lymphoma & myeloma, 2008, Volume: 8, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow	2008
A case series of 48 patients treated with thalidomide. Journal of drugs in dermatology : JDD, 2008, Volume: 7, Issue:8 Topics: Adult; Female; Humans; Immunosuppressive Agents; Leprostatic Agents; Male; Middle Aged; Peripheral N	2008
Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. Journal of the peripheral nervous system : JPNS, 2008, Volume: 13, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte	2008
Cutaneous involvement in multiple myeloma and bortezomib. Annals of hematology, 2009, Volume: 88, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Fema	2009
Clinical and electrophysiological evaluation of patients with thalidomide-induced neuropathy. Acta neurologica Belgica, 2009, Volume: 109, Issue:2 Topics: Action Potentials; Adolescent; Adult; Aged; Electromyography; Electrophysiology; Female; Humans; Imm	2009
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. European journal of haematology, 2010, Volume: 84, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib;	2010
Thalidomide-induced phrenic nerve paralysis. Leukemia & lymphoma, 2010, Volume: 51, Issue:2 Topics: Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Dis	2010
Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. Journal of the National Comprehensive Cancer Network : JNCCN, 2010, Volume: 8 Suppl 1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Asthenia; Boronic Acids; Bortezomib; Humans; Multipl	2010
New uses for older drugs: the tales of aspirin, thalidomide, and gabapentin. Mayo Clinic proceedings, 2010, Volume: 85, Issue:6 Topics: Amines; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Aspirin; Cyclohexanecarboxylic Aci	2010
Lenalidomide for bortezomib-resistant multiple myeloma. Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:9 Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Health Status Ind	2010
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Mar-01, Volume: 29, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Gene	2011
Peripheral nerve injury leads to working memory deficits and dysfunction of the hippocampus by upregulation of TNF-α in rodents. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2011, Volume: 36, Issue:5 Topics: Animals; Disease Models, Animal; Electric Stimulation; Excitatory Postsynaptic Potentials; Hippocamp	2011
Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab. Journal of pediatric gastroenterology and nutrition, 2012, Volume: 54, Issue:1 Topics: Adalimumab; Adolescent; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu	2012
Anti-myelin associated glycoprotein neuropathy responding to lenalidomide. Leukemia research, 2011, Volume: 35, Issue:11 Topics: Aged; Antineoplastic Agents; Demyelinating Diseases; Humans; Immunoglobulin M; Lenalidomide; Male; M	2011
Thalidomide in 42 patients with prurigo nodularis Hyde. Dermatology (Basel, Switzerland), 2011, Volume: 223, Issue:2 Topics: Female; Humans; Immunosuppressive Agents; Male; Peripheral Nervous System Diseases; Prurigo; Retrosp	2011
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. British journal of haematology, 2012, Volume: 156, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte	2012
Late-onset neurological symptoms in thalidomide-exposed subjects: a study of an Australasian cohort. European journal of neurology, 2013, Volume: 20, Issue:3 Topics: Antiemetics; Australasia; Australia; Cohort Studies; Disease Progression; Female; Humans; Male; Midd	2013
Initial success, frequent recurrence: tomorrow's multiple myeloma treatments and the value of subtype analysis. Interview with David Siegel. The American journal of managed care, 2012, Volume: 18, Issue:5 Spec No. Topics: Antineoplastic Agents; Cancer Vaccines; Humans; Lenalidomide; Managed Care Programs; Multiple Myelom	2012
Multiple myeloma, version 1.2013. Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Jan-01, Volume: 11, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; B	2013
Thalidomide-induced neuropathy. Mayo Clinic proceedings, 2002, Volume: 77, Issue:12 Topics: Humans; Immunosuppressive Agents; Multiple Myeloma; Peripheral Nervous System Diseases; Thalidomide	2002
Toxic neuropathy in patients with pre-existing neuropathy. Neurology, 2003, Jan-28, Volume: 60, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Dose-Respo	2003
Thalidomide-induced neuropathy: a ganglionopathy? Neurology, 2003, Mar-11, Volume: 60, Issue:5 Topics: Aged; Evoked Potentials, Somatosensory; Gait Disorders, Neurologic; Ganglia, Spinal; Humans; Magneti	2003
Neuropathy after intake of thalidomide (distaval). British medical journal, 1961, Sep-30, Volume: 2, Issue:5256 Topics: Central Nervous System Depressants; Hypnotics and Sedatives; Nervous System; Peripheral Nervous Syst	1961
The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. The New England journal of medicine, 1962, Dec-06, Volume: 267 Topics: Ectromelia; Fetal Diseases; Peripheral Nervous System Diseases; Thalidomide	1962
The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. The New England journal of medicine, 1962, Dec-13, Volume: 267 Topics: Congenital Abnormalities; Fetal Diseases; Humans; Neurology; Peripheral Nervous System Diseases; Tha	1962
Neuropathy, hypoglycaemia, and adrenal dysfunction during treatment with thalidomide. British medical journal, 1962, Aug-04, Volume: 2, Issue:5300 Topics: Adrenal Cortex; Hypnotics and Sedatives; Hypoglycemia; Neurology; Peripheral Nervous System Diseases	1962
[Thalidomide neuropathy]. Svenska lakartidningen, 1963, Feb-28, Volume: 60 Topics: Humans; Neuritis; Paralysis; Paresthesia; Peripheral Nervous System Diseases; Thalidomide	1963
BLOOD PYRUVIC ACID IN THALIDOMIDE NEUROPATHY. British medical journal, 1963, Oct-19, Volume: 2, Issue:5363 Topics: Blood Chemical Analysis; Chromatography; Geriatrics; Humans; Metabolism; Peripheral Nervous System D	1963
THALIDOMIDE NEUROPATHY. British medical journal, 1963, Dec-14, Volume: 2, Issue:5371 Topics: Neurology; Peripheral Nervous System Diseases; Thalidomide; Toxicology	1963
Thalidomide in Crohn disease and the risk of peripheral neuropathy. Journal of pediatric gastroenterology and nutrition, 2003, Volume: 37, Issue:4 Topics: Child; Crohn Disease; Humans; Peripheral Nervous System Diseases; Thalidomide	2003
Thalidomide and dexamethasone therapy of myeloma in a patient with previously untreated B-chronic lymphocytic leukemia. American journal of hematology, 2003, Volume: 74, Issue:3 Topics: Aged; Clone Cells; Dexamethasone; Fatal Outcome; Female; Humans; Leukemia, Lymphocytic, Chronic, B-C	2003
Thalidomide neuropathy: too much or too long? Neurology, 2004, Jun-22, Volume: 62, Issue:12 Topics: Humans; Immunosuppressive Agents; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Thali	2004
Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus. Neurology, 2004, Jun-22, Volume: 62, Issue:12 Topics: Adult; Electrophysiology; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Middle A	2004
Thalidomide neuropathy in childhood. Neuromuscular disorders : NMD, 2005, Volume: 15, Issue:2 Topics: Action Potentials; Adolescent; Brain Neoplasms; Child; Crohn Disease; Disease Progression; Electromy	2005
Thalidomide in Crohn disease. Journal of pediatric gastroenterology and nutrition, 2005, Volume: 40, Issue:2 Topics: Clinical Trials as Topic; Crohn Disease; Diagnosis, Differential; Dose-Response Relationship, Drug;	2005
Multiple myeloma. The New England journal of medicine, 2005, Feb-24, Volume: 352, Issue:8 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous Syste	2005
Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. The American journal of medicine, 2005, Volume: 118, Issue:3 Topics: Adult; Aged; Analysis of Variance; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressi	2005
Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients. Lupus, 2005, Volume: 14, Issue:6 Topics: Adolescent; Adult; Aged; Brazil; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Disc	2005
Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus. Autoimmunity, 2005, Volume: 38, Issue:7 Topics: Adult; Dose-Response Relationship, Drug; Electrophysiology; Female; Humans; Immunosuppressive Agents	2005
[Potential side effects of thalidomide]. La Revue du praticien, 2006, Jan-15, Volume: 56, Issue:1 Topics: Constipation; Disorders of Excessive Somnolence; Drug Eruptions; Humans; Immunosuppressive Agents; L	2006
Thalidomide-induced neuropathy: treatment by decompression of peripheral nerves. Plastic and reconstructive surgery, 2006, Volume: 117, Issue:7 Topics: Antineoplastic Agents; Decompression, Surgical; Humans; Immunosuppressive Agents; Lower Extremity; M	2006
Peripheral neuropathy associated with nodular prurigo. Clinical and experimental dermatology, 2007, Volume: 32, Issue:1 Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Neural Conduction; Peripheral Nervous System Disease	2007
The troublesome toxicity of peripheral neuropathy with thalidomide. Leukemia & lymphoma, 2006, Volume: 47, Issue:11 Topics: Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Risk Factors; Thalidomide	2006
Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF. Molecular therapy : the journal of the American Society of Gene Therapy, 2007, Volume: 15, Issue:1 Topics: Animals; Apoptosis; Cells, Cultured; Drug Therapy, Combination; Electrophysiology; Endothelial Cells	2007
Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma. Oncology, 2007, Volume: 72 Suppl 1 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Ankle; Carcinoma, Hepatocellular; Edema; Fe	2007
Thalidomide and sensory neurotoxicity: a neurophysiological study. Journal of neurology, neurosurgery, and psychiatry, 2008, Volume: 79, Issue:11 Topics: Adult; Angiogenesis Inhibitors; Disability Evaluation; Female; Humans; Lupus Erythematosus, Cutaneou	2008
Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome. Journal of neurology, neurosurgery, and psychiatry, 2008, Volume: 79, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Dexamethasone; Dr	2008
Scleromyxoedema with associated peripheral neuropathy: successful treatment with thalidomide. Clinical and experimental dermatology, 2008, Volume: 33, Issue:5 Topics: Aged; Dermatologic Agents; Female; Humans; Peripheral Nervous System Diseases; Scleromyxedema; Thali	2008
Thalidomide-induced peripheral neuropathy. Effect of serum factor on nerve cultures. Archives of dermatology, 1984, Volume: 120, Issue:11 Topics: Adult; Aged; Animals; Cells, Cultured; Female; Fetus; Ganglia, Spinal; Humans; Male; Middle Aged; Ne	1984
[Electrophysiologic changes in thalidomide neuropathy in the treatment of discoid lupus erythematosus]. EEG-EMG Zeitschrift fur Elektroenzephalographie, Elektromyographie und verwandte Gebiete, 1982, Volume: 13, Issue:4 Topics: Electromyography; Humans; Lupus Erythematosus, Discoid; Median Nerve; Motor Neurons; Neural Conducti	1982
Safety of thalidomide. BMJ (Clinical research ed.), 1994, May-28, Volume: 308, Issue:6941 Topics: Consumer Product Safety; Humans; Leprosy; Peripheral Nervous System Diseases; Thalidomide	1994
Thalidomide-induced neuropathy and genetic differences in drug metabolism. European journal of clinical pharmacology, 1995, Volume: 49, Issue:1-2 Topics: Acetylation; Adrenergic Agents; Adult; Anti-Infective Agents; Debrisoquin; Dermatologic Agents; Fema	1995
The place of thalidomide in the treatment of inflammatory disease. Lupus, 1996, Volume: 5, Issue:4 Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents, Non-Steroidal; Contraindications; Cytokines;	1996
Thalidomide-induced perioral neuropathy. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 1997, Volume: 84, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adju	1997
Thalidomide neuropathy: role of F-wave monitoring. Muscle & nerve, 2000, Volume: 23, Issue:8 Topics: Adult; Aged; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Neural Conduct	2000
A neuroimmune interaction in painful peripheral neuropathy. The Clinical journal of pain, 2000, Volume: 16, Issue:3 Suppl Topics: Animals; Constriction, Pathologic; Cyclosporine; Dose-Response Relationship, Drug; Immunosuppressive	2000
Lack of peripheral neuropathy in Beagle dogs after 53 weeks oral administration of thalidomide capsules. Human & experimental toxicology, 2000, Volume: 19, Issue:11 Topics: Action Potentials; Administration, Oral; Animals; Capsules; Dogs; Dose-Response Relationship, Drug;	2000
Thalidomide usage in Wales: the need to follow guidelines. The British journal of dermatology, 2001, Volume: 144, Issue:2 Topics: Dermatologic Agents; Dermatology; Drug Utilization; Guideline Adherence; Humans; Informed Consent; N	2001
Thalidomide-induced sensory neuropathy. Journal of pediatric gastroenterology and nutrition, 2001, Volume: 32, Issue:3 Topics: Child; Child, Preschool; Crohn Disease; Humans; Male; Peripheral Nervous System Diseases; Thalidomid	2001
The rehabilitation of thalidomide. Journal of the International Association of Physicians in AIDS Care, 1998, Volume: 4, Issue:1 Topics: Abnormalities, Drug-Induced; CD4 Lymphocyte Count; Conflict of Interest; Contraception; Drug Approva	1998
Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions. Seminars in oncology, 2001, Volume: 28, Issue:6 Topics: Adult; Angiogenesis Inhibitors; Drug Therapy, Combination; Female; Glucocorticoids; Hematopoietic St	2001
Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia, 2002, Volume: 16, Issue:1 Topics: Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Blood Transf	2002
Editorial: Postscript to thalidomide. Lancet (London, England), 1975, Mar-08, Volume: 1, Issue:7906 Topics: Abnormalities, Drug-Induced; Adult; Age Factors; Child; Child, Preschool; Ectodermal Dysplasia; Fema	1975
Thalidomide anomalies of the ear. Archives of otolaryngology (Chicago, Ill. : 1960), 1976, Volume: 102, Issue:7 Topics: Abducens Nerve; Abnormalities, Drug-Induced; Adolescent; Child; Deafness; Ear; Ear, External; Ear, I	1976
Segmental embryonic peripheral neuropathy. Pediatric radiology, 1975, Jun-13, Volume: 3, Issue:3 Topics: Abnormalities, Drug-Induced; Animals; Arm; Bone and Bones; Extremities; Humans; Leg; Limb Deformitie	1975
Thalidomide peripheral neuropathy. Tropical doctor, 1992, Volume: 22, Issue:3 Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Male; Nigeria; Peripheral Nervous System Diseases; T	1992
Thalidomide neuropathy. The New England journal of medicine, 1992, Sep-03, Volume: 327, Issue:10 Topics: Graft vs Host Disease; Humans; Peripheral Nervous System Diseases; Thalidomide	1992
Use of thalidomide in leprosy. BMJ (Clinical research ed.), 1991, Aug-24, Volume: 303, Issue:6800 Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Peripheral Nervous System Diseases; Thalidomide	1991
Experimental thalidomide neuropathy: the morphological correlate of reduced conduction velocity. Acta neuropathologica, 1985, Volume: 65, Issue:3-4 Topics: Animals; Female; Microscopy, Electron; Myelin Sheath; Nerve Degeneration; Neurons, Afferent; Periphe	1985
Thalidomide therapy. An open trial. International journal of dermatology, 1985, Volume: 24, Issue:2 Topics: Adult; Aged; Central Nervous System Diseases; Erythema Multiforme; Female; Humans; Lichen Planus; Lu	1985
Development of polyneuropathy during thalidomide therapy. The British journal of dermatology, 1985, Volume: 112, Issue:4 Topics: Action Potentials; Adult; Aged; Female; Humans; Leg; Male; Middle Aged; Neural Conduction; Neurons,	1985
[Neuropathies caused by thalidomide]. Revue neurologique, 1985, Volume: 141, Issue:11 Topics: Acute Disease; Adult; Female; Humans; Lupus Erythematosus, Discoid; Male; Microscopy, Electron; Midd	1985
Thalidomide-induced peripheral neuropathy. A prospective clinical, neurophysiological and pharmacogenetic evaluation. Journal of neurology, 1986, Volume: 233, Issue:2 Topics: Acetylation; Adolescent; Adult; Electromyography; Evoked Potentials; Female; Humans; Hydroxylation;	1986
Thalidomide neurotoxicity and rheumatoid arthritis. Arthritis and rheumatism, 1986, Volume: 29, Issue:10 Topics: Arthritis, Rheumatoid; Female; Humans; Peripheral Nervous System Diseases; Thalidomide	1986
Treatment of erythema nodosum leprosum with thalidomide. Lancet (London, England), 1973, Sep-08, Volume: 2, Issue:7828 Topics: Axons; Biopsy; Erythema Nodosum; Humans; Leprosy; Peripheral Nervous System Diseases; Thalidomide	1973
Letter: Thalidomine neuropathy and leprous neuritis. Lancet (London, England), 1974, Feb-02, Volume: 1, Issue:7849 Topics: Diagnosis, Differential; Humans; Hypesthesia; Leprosy; Mycobacterium leprae; Neuritis; Peripheral Ne	1974
Thalidomide neuropathy. Lancet (London, England), 1969, Apr-05, Volume: 1, Issue:7597 Topics: Animals; Humans; Peripheral Nervous System Diseases; Thalidomide	1969
[Clinical aspects and therapy of the so-called Contergan-polyneuropathy]. Der Nervenarzt, 1966, Volume: 37, Issue:5 Topics: Adult; Aged; Central Nervous System Diseases; Female; Humans; Male; Middle Aged; Nerve Degeneration;	1966
The fibre size and content of the radial and sural nerves. Journal of neurology, neurosurgery, and psychiatry, 1968, Volume: 31, Issue:5 Topics: Adolescent; Adult; Age Factors; Aged; Alcoholism; Extremities; Female; Humans; Male; Middle Aged; My	1968
Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study. Journal of neurology, neurosurgery, and psychiatry, 1968, Volume: 31, Issue:6 Topics: Action Potentials; Adult; Aged; Female; Follow-Up Studies; Humans; Leg; Median Nerve; Middle Aged; N	1968
Toxic chemicals and peripheral neuropathy. Proceedings of the Royal Society of Medicine, 1969, Volume: 62, Issue:2 Topics: Acrylates; Cooking; Cresols; Humans; Occupational Diseases; Oils; Peripheral Nervous System Diseases	1969
[Polyneuritis and polyneuropathies due to drug therapy]. Revista clinica espanola, 1968, Sep-30, Volume: 110, Issue:6 Topics: Anticonvulsants; Humans; Nitrofurantoin; Peripheral Nervous System Diseases; Polyneuropathies; Thali	1968
[Drug-induced polyneuropathy]. Therapeutische Umschau. Revue therapeutique, 1970, Volume: 27, Issue:6 Topics: Abnormalities, Drug-Induced; Adult; Animals; Drug-Related Side Effects and Adverse Reactions; Female	1970

Intervention	Participants (Number)
Glioblastoma Multiforme Stratum	4
Anaplastic Glioma Stratum	2

thalidomide and Peripheral Nerve Diseases

Research Excerpts

Research

Studies (190)

Authors

Clinical Trials (27)

Trial Overview

Trial Outcomes

Mean Neuropathy Severity Score (FACT-GOG-Ntx Total Score Assessment)

Clinical Response to Treatment

Peripheral Motor and Sensory Neuropathy (Grade 2 and Higher)

The Time to Response

Serum Levels of Hydroxycloroquine

Serum Levels of Thalidomide

Engraftment Failure Transplant Related Mortality

Number of Participants With Adverse Events

Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)

Number of Participants With Progression Free Survival in Cohort A Th1 (Type 1 T Helper Cells)/Tc1 (T Cytotoxic Cells, Type 1) Rapa Prevention of Relapse

Number of Patients Who Developed a Partial Response (PR)+Complete Response (CR) in Cohort B at Any Time Point Post Therapy With PR/CR Being Maintained Until Study Completed

Number of Patients With an Adverse Event Attributable to the Investigational Therapy

Average Number of Cluster of Differentiation 34 (CD34) Cells Collected (Per kg Recipient Body Weight (BW))

Median and Standard Deviation of Cluster of Differentiation 34 (CD34) Cells Collected (Per Kg Recipient Body Weight) (BW)

Number of Hematopoietic Progenitor Cell (HPC) Apheresis Products Collected and Cryopreserved for Subsequent Use in Autologous Hematopoietic Cell Transplantation (AHCT) in Subjects With Plasma Cell Myeloma (PCM)

Number of Participants With Serious and Non-Serious Adverse Events

Percentage of Patients Achieving at Least 2 x 10^6 Cluster of Differentiation 34 (CD34) Cells Per Kg Recipient Body Weight on Day 1 of Apheresis

Percentage of Patients Requiring 2 Days to Achieve at Least 2 x 10^6 Cluster of Differentiation 34 (CD34) Cells Per Kg Recipient Body Weight

Percentage of Patients That Achieved ≥ 2 x 10^6 But Less Than 5 x 10^6 Cluster of Differentiation 34 (CD34) Cells/kg (Day One Collection)

Range of Cluster of Differentiation 34 (CD34) Cells Collected

25th and 75th Percentile Values of Cluster of Differentiation 34 (CD34) Cells Collected

Percentage of Patients That Achieved or Did Not Achieve 5 x 10^6 Cluster of Differentiation 34 (CD34) Cells/kg

Percentage of Patients That Required Plerixafor + Granulocyte-colony Stimulating Factor (G-CSF) And Only G-CSF (no Plerixafor)

Complete Response

Overall Response Rate

Evaluation of Stringent Complete Response, Complete Response, and Very Good Partial Response Rate (sCR + CR + VGPR Rate).

Number of Participants Serious Adverse Events

Number of Participants Who Progressed at 12 Months

Progression Free Survival (PFS)

The Number of Participants With Adverse Events

Time to Progression

The Number of Participants With Adverse Events

Reviews

Trials

Other Studies